Protocol I8F-MC-GPHR(d) 
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety 
of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)
[STUDY_ID_REMOVED]    
Approval 
Date: 19-Nov-2020
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical 
investigation of Tirzepatide (LY3298176) unless such persons are bound by a confidentiality agreement with Eli Lilly and Company 
or its subsi diaries.  
Note to Regulatory Authorities:   This document may contain protected personal data and/or commercially confidential 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any
public release.  In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Protocol Title :A Randomized, Double -Blind, Placebo -Controlled Phase 2 Study  Comparing 
the Efficacy and Safet y of Tirzepatide versus Placebo in Pat ients with Nonalcoholic 
Steatohepatit is (NASH)
Protocol Number: I8F-MC-GPHR
Amendment Number: d
Compound Number: LY3298176
Study Phase: Phase 2
Short Title: Tirzepatide versus placebo in NASH
Acronym: SYNERGY -NASH
Sponsor Name: Eli Lilly and Com pany
Legal Registered Address: Indianapolis, Indiana USA 46285 
Regulatory Agency Identifier Numbers
IND: 143191
EudraCT:  2019-001550-26
Approval Date:   Protocol Amendment ( d)Electronically Signed and Approved by Lillyondate 
provided below.
Approval Date: 19-Nov-2020 GMT
CONFIDENTIAL  Protocol I8F -MC-GPHR( d) 
LY3298176  2 Protocol Amendment Summary of Changes Table 
DOCUMENT HISTORY  
Document  Date  
Amendment C  15 November 2019  
Amendment B  21 October 2019  
Amendment A  13 August 2019  
Original Protocol  26 July 2019  
Amendment d This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the  European Union 
Overall Rationale for Amendment d:  
A recently published algorithm, the FibroScan-AST ( FAST ) score, has optimized the use of 
transient elastography (FibroScan) and a laboratory test (aspartate aminotransferase [ AST]) to 
identif y patients who have nonalcoholic steatohepatitis (NASH) with a nonalcoholic fatty liver 
disease ( NAFLD) Activity Score (NAS) ≥4 and fibrosis stage s ≥2, which is the target population 
for this study (Newsome et al. 2020) .  Review and analyses of early blinded biopsy data from 
Study I8F -MC-GPHR indicate that use of the FAST  score would reduce the number of patients 
who undergo liver biopsies that do not qualify for inclusion into the study.   Therefore, the FAST 
score is added as an additional screening criterion for patients who have a reliable FibroScan.  
Furthermore , the lower limit of AST for inclusion has been increased  to reduce the number of 
screen -fails by biopsy. 
The protocol is also being amended to put procedures into place that  would enabl e participants to 
continue safely in the study and maintain the integrity of the study under exceptional 
circumstances.  
Section # and Name  Description of Change  Brief Rationale  
1.3. Schedule of 
Activities  (SoA)  Added FAST score  to screening  Included the FAST score in the 
Schedule of Activities .  
 Added footnote to im aging (t ransient 
elastography and MRI) to allow a longer visit window at Visit 10 (Week 26)  The visit window for  obtaining the 
transient elastography and MRI  were 
increased to ± 2 weeks at V isit 10 due to challenges in scheduling the procedures.  The enhanced visit window for im aging does not affect 
the quality of the data or the study.  
 Added footnote  reference regarding tim ing of 
imaging at Week 52.  Correction of an oversight.  
Reference was already in the 
footnote (p) but was not  in the SOA.  
5.1. Inclusion Criteria  (#5) Added FAST score  and increased the 
screening lower AST lower limit from >20 U/L 
to >23 U/L 
(#5b) Increased screening AST lower limit from 
>20 U/L to >23 U/L  for patients whose 
FibroScan is not reliable  Reduce the number of patients 
undergoing a biopsy that do not qualify for the study.  
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 38.1.3.3. Transient 
Elastography (TE)Added description of the FAST score Provided description of the FAST 
score.
9.3. Populations for 
AnalysesDeleted text
Modified previously defined populations in the 
study table by adding more granularity to the 
description
Added Safety Analysis Set (SS) populationDeleted text is covered in the table 
below.
Differentiate sbetween efficacy and 
safety analys es sets more clearly .
For safety analysis purposes by 
addingsafetyfollow-up period to 
FAS.
9.4.4. Safety Analyses Replaced FAS with SS With addition of SS population ,
safety analysis is conducted using 
SS.
10.2. Appendix 2: 
Clinical Laboratory 
TestsAdded FAST score The central laboratory will be 
calculating the FAST score ;
therefore,FAST has been added to 
laboratory calculatio ns.
10.10.Appendix 10. 
Provisions for Changes 
in Study Conduct 
During Exceptional 
CircumstancesAdded procedures for exception alcircumstances There may be exceptional
circumstances that may limit the 
ability of the investigators, 
participants, or both to attend on -site 
visits or to conduct planned study 
procedures .Procedures have been 
added that would enableparticipants 
to continue safely in the study and 
maintain the integrity of the study .
11.References Added Newsome reference for FAST score Added Newsome reference that
gives the background to the FAST 
score that beingincorporated into the
Inclusion Criteria.
Updated Hartman et al reference Published journal article cited 
instead of abstract
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis....................................................................................................................... 7
1.2. Schema....................................................................................................................... 10
1.3. Schedule of Act ivities (SoA) ...................................................................................... 11
2. Introduction .............................................................................................................. 16
2.1. Study Rationale.......................................................................................................... 16
2.2. Background................................................................................................................ 16
2.3. Benefit/Risk Assessment ............................................................................................ 17
3. Objectives and Endpoints ......................................................................................... 18
4. Study Design ............................................................................................................. 21
4.1. Overall Design ............................................................................................................ 21
4.2. Scientific Rationale for Study Design......................................................................... 22
4.3. Justification for Dose .................................................................................................. 23
4.4. End of Study  Definition.............................................................................................. 23
5. Study Population ...................................................................................................... 24
5.1. InclusionCriteria........................................................................................................ 24
5.2. Exclusion Criteria....................................................................................................... 28
5.2.1. Rationale for Sel ect Exclusion Criteria....................................................................... 32
5.3. Lifestyle Considerat ions............................................................................................. 32
5.4. Screen Failures ........................................................................................................... 32
6. S tudy Intervention .................................................................................................... 34
6.1. Study Intervent ion(s) Administered ............................................................................ 34
6.1.1. Medical Devices ......................................................................................................... 34
6.2. Preparation/Handling/Storage/Accountabilit y............................................................. 34
6.3. Measures to Minimize Bias:  Rando mization and Blinding ......................................... 35
6.4. Study Intervent ion Compliance ................................................................................... 35
6.5. Concomitant Therapy .................................................................................................36
6.5.1. Hyperglycemia Rescue ............................................................................................... 36
6.5.2. Management of Participants with Gastrointestinal Symptoms ..................................... 38
6.6. Dose Modificat ion...................................................................................................... 38
6.7. Intervention after the End of the Study ........................................................................ 38
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 39
7.1. Discontinuati on of Study Intervent ion........................................................................ 39
7.1.1. Interrupti on of Study Intervent ion............................................................................... 40
7.1.2. Restarting Study Drug after Interruption ..................................................................... 40
7.1.3. Interrupti on/Discont inuation due to a Hepatic Event or Liver 
Test Abnormalit y........................................................................................................ 40
7.2. Participant Discontinuation/Wit hdrawal fro m the Study............................................. 41
7.2.1. Discontinuati on of Inadvertent ly Enrolled Patients ..................................................... 42
7.3. Lost to Follow -Up...................................................................................................... 42
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 58. Study Assessments and Procedures ......................................................................... 43
8.1. Efficacy Assessments .................................................................................................43
8.1.1. P rimary Efficacy Assessment ...................................................................................... 43
8.1.2. Secondary  Efficacy Assessments ................................................................................ 45
8.1.3. Exploratory Efficacy Assessments .............................................................................. 46
8.2. Safety Assessments .................................................................................................... 49
8.2.1. Physical Examinat ions................................................................................................ 49
8.2.2. Vital Signs.................................................................................................................. 49
8.2.3. Electrocardiograms ..................................................................................................... 49
8.2.4. Clinical Safety  Laboratory  Assessments ..................................................................... 50
8.3. AdverseEvents and Serious Adverse Events .............................................................. 53
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Information................................................................................................................. 55
8.3.2. Follow-Up of AEs and SAEs ...................................................................................... 55
8.3.3. Regulatory  Reporting Requirements for SAEs ............................................................ 55
8.3.4. Pregnancy ................................................................................................................... 56
8.3.5. Medical Device Incidents (Including Malfunct ions).................................................... 56
8.3.6. Complaint Handling ................................................................................................... 56
8.3.7. Adverse Events of Special Interest .............................................................................. 57
8.4. Treatment of Overdose ............................................................................................... 62
8.5. Pharmacokinet ics........................................................................................................ 62
8.6. Pharmacodynamics ..................................................................................................... 63
8.7. Genetics..................................................................................................................... 63
8.7.1. Whole Blood Samples for Pharmacogenet ic Research ................................................ 63
8.8. Biomarkers................................................................................................................. 63
8.9. Medical Resource Utilizat ion and Healt h Economics .................................................. 64
9. Statistical Considerations ......................................................................................... 65
9.1. Statistical Hypotheses .................................................................................................65
9.2. Sample Size Determinat ion......................................................................................... 65
9.3. Populations for Analyses ............................................................................................ 65
9.4. Statistical Analyses..................................................................................................... 66
9.4.1. General Statist ical Considerat ions............................................................................... 66
9.4.2. Treatment Group Comparabilit y................................................................................. 67
9.4.3. Efficacy Analyses ....................................................................................................... 67
9.4.4. Safety Analyses .......................................................................................................... 68
9.4.5. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 68
9.4.6.Evaluation of Immunogenicit y.................................................................................... 69
9.4.7. Subgroup Analyses ..................................................................................................... 69
9.5. Interim Analyses ......................................................................................................... 69
10. Supporti ng Documentation and Operational Considerations ................................ 70
10.1. Appendix 1:  Regulatory , Ethical, and Study  Oversight 
Considerations ............................................................................................................ 70
10.1.1. Regulatory  and Ethical Considerat ions........................................................................ 70
10.1.2. Informed Consent Process .......................................................................................... 70
10.1.3. Data Protection ........................................................................................................... 71
10.1.4. Dissemination of Clinical Study  Data......................................................................... 71
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 610.1.5. Data Qualit y Assurance .............................................................................................. 72
10.1.6. Source Documents ...................................................................................................... 73
10.1.7. Study and Site Closure................................................................................................ 73
10.1.8. Publication Policy....................................................................................................... 74
10.2. Appendix 2:  Clinical Laboratory  Tests....................................................................... 75
10.3. Appendix 3:  Liver Safet y:  Actions and Fo llow-Up Assessments ............................... 78
10.4. Appendix 4:  Definit ions of Hypoglycemia .................................................................79
10.5. Appendix 5:  World Healt h Organization Standardized Protocols 
for the Measurement of Height and Weight .................................................................80
10.6. Appendix 6:  Diet and Physical Act ivity Suggestions for Sites 
without Programs ....................................................................................................... 81
10.6.1. Diet............................................................................................................................ 81
10.6.2. Physical Act ivity........................................................................................................ 81
10.7. Appendix 7:  Medical Device Incidents:  Definit ion and 
Procedures for Recording, Evaluat ing, Follow-Up, and Reporting .............................. 83
10.8. Appendix 8:  Contraceptive Guidance and Collection of 
Pregnancy Information ............................................................................................... 85
10.9. Appendix 9:  List of Prohibited Medications by Protocol Section ................................ 87
10.10. Appendix 10:  Provi sions for Changes in Study  Conduct During 
Exceptional Circumstances ......................................................................................... 88
10.11. Appendix 11:  Protocol Amendment History .............................................................. 92
10.12. Appendix 12:  Abbreviat ions...................................................................................... 97
11. References ............................................................................................................... 102
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 71. Protocol Summary
1.1. Synopsis
Protocol Title: A Randomized, Double -Blind, Placebo -Controlled Phase 2 Study 
Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with 
Nonalcoholic Steatohepatitis (NASH)
Short Title: Tirzepatide versus placebo in NASH
Rationale :  
Tirzepatide is a 39-amino acid synt hetic peptide with agonist activit y at both the glucose -
dependent insulinotropic polypept ide gastric inhibitory  polypept ide(GIP) receptor and the 
glucagon-like peptide -1 receptor.  Its structure is based on the GIP sequence and include s a C20 
fatty diacid moiety.  It is administered once weekly by subcutaneous (SC) inject ion.  Treatm ent 
with tirzepatide results in glucose lowering, weight loss, and improved metabo lic health in 
patients with type 2 diabetes m ellitus (Frias et al. 2018). The beneficial effects of weight loss in 
patients with nonalcoholic steatohepatit is (NASH) are well -characteri zed (Promrat et al. 2010; 
Vilar-Gomez et al . 2015).  Study  I8F-MC-GPHR (GPHR) will invest igate the effects of 52 -week 
treatment with tirzepatide in patients with biopsy -proven NASH.  The primary  endpoint is 
NASH reso lution with no worsening of fibrosis, based on liver histology .  These data will 
support dose selection for Phase3.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 8Objectives and Endpoint s
Objectives Endpoints
Primary
To demonstrate that ti rzepatide 5 mg, 10 mg 
or 15mg administered SC QW is superior to 
placebo for NASH resol ution with no 
worsening of fibrosis at Week 52. Proportion of participants cl assified wi th 
absence of NASH with no worsening of 
fibrosis on liver histology as defined in 
Section 8.1.1.
Secondary
To demonstrate that ti rzepatide 5 mg, 10 mg 
or 15 mg administered SC QW is superior to 
placebo at Week 52 for: 
From baseline:
Regressio n of fibrosis with no worsening 
of NASHProportion of participants wi th ≥1 point 
decrease in fibrosis stage with no 
worsening of NASH on liver histology
Prevention of fibrosis progression Proportion of participantswith ≥1 point 
increase in fibrosis stage on liver 
histology
Decreasing NAS by  ≥2 points Proportion of participants that achi eve a 
≥2 point decrease in NAS on liver 
histology, with ≥1 point reducti on in at 
least 2 NAS components (steatosis, 
hepatocellular ballooning, lobular 
inflammat ion)
Decreasing liver fat content Mean abso lute change in liver fat content 
by MRI-PDFF
Decreasing body  weight Mean change in body  weight
Abbreviations: MRI-PDFF = magnetic resonance imaging –proton density fat fraction ;NAS = nonalcoholic fatty 
liver disease ( NAFLD)activity score; NASH = nonalcoholic steatohepatitis; SC = subcutaneous; QW = once 
weekly.
Overall Design :
StudyGPHR is a Phase 2, m ulticenter, randomized, double- blind, parallel group, 
placebocontrolled, treat -through study  to evaluate the safet y and efficacy of tirzepatide 
compared with placeboin patients with nonalcoholic steatohepatit is.  
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 9Disclosure Statement :
This is a parallel, double-blinded treatmentstudy with 4treatment groups.
Number of Participants:
Approximately 196participants will be randomly  assigned to study  intervention such that 
approximately  157evaluable participants com plete the study . 
Intervention Groupsand Duration :
Participants will be randomized in a 1:1:1 :1ratio to receive:  
Tirzepatide 15 mg SCevery week 
Tirzepatide 10 mg SCevery week
Tirzepatide 5 mg SC every  week
Placebo SCevery week
The maximum total duration of study participat ion for each participant is up to68 weeks, across 
the following study  periods:  
Screening:  approximately  6 weeks andshould not exceed 12 weeks
Treatment:  52 weeks
Safety follow-up:  4 weeks
Data Monitoring Committee: No
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 101.2. Schema
Abbreviation:  QW = once weekly.
*Screening procedures may take longer or shorter than 6 weeks and will not be considered a protocol deviation.

CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 111.3. Schedule of Activities (SoA)
Visit 1a2a,b3a4567891011121314801ET
Week of Treatment 640148121620263240485256
Study Day/(Dose number) 0/(1)7/(2)28/(5)56/(9)84/(13)112/(17)140/(21)182/(27)224/(33)280/(41)336/(49)364/ND392/ND
Visit Window (days) ±3±3±7±7±7±7±7±10±14 ±7±7±7
Fasting Visit X XXXXXXXXXXXXXX
Administrative
Informed consent X
Diabetes/therapy X X X X X X X X X X X X X X
Medical history X
Health habits (alcohol use, tobacco 
use)X
Cardiovascular risk factors history X
Alcohol use questionnaire (AUDIT) X X X
Concomitant medications X X X X X X X X X X X X X X X
Inclusion/Exclusion X X
Randomization X
IWRS X X X X X X X X X X X X X X X X
BG meter/supplies, counseling 
(T2DM patients only)(resupply as 
needed)X
Diet, physical activity coaching X X X X X X
Study diary, dispense X X X X X X X X X X X
Review diaries for BG values (T2DM 
patients only )X X X X X X X X X X X X X X
Subcutaneous injection trainingcX X
Study drug and injection supplies, 
dispensed X X X X X X X X X X X
Participant returns study drug 
suppliesX X X X X X X X X X X
Drug accountability and compliance X X X X X X X X X X X X X
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 12Visit 1a2a,b3a4567891011121314801ET
Week of Treatment 640148121620263240485256
Study Day/(Dose number) 0/(1)7/(2)28/(5)56/(9)84/(13)112/(17)140/(21)182/(27)224/(33)280/(41)336/(49)364/ND392/ND
Visit Window (days) ±3±3±7±7±7±7±7±10±14 ±7±7±7
Fasting Visit X XXXXXXXXXXXXXX
Participant Demographics
Age/Gender X
Race/Ethnicity X
Clinical Variab les
Adverse events X X X X X X X X X X X X X X
Physical examinationeX
Height X X X
Weight X X X X X X X X X X X X X X
Waist circumference X X X X X X X X X X X X X X
Vital signs (BP ,pulse rate , and body 
temperature )X X X X X X X X X X X X X X
Dilated fundoscopic examinationfX
Diagnostics ( Safety)
Screening laboratory testsgX
Transferrin saturation X
TSH X
Pregnancy testhX X X X X X X X X X X X X X
Estradiol, FSH, LHiX
Chemistry panel X X X X X X X X X X X X X
FIB-4jX X X X X X X X X X X
Lipid panel X X X X X X X X
eGFR X X X X X X X X X X X X
Hematology X X X X X X X X X X X X
APTT and PT (INR) X X X X X X X X
Urinalysis X X X X X X X
Urine albumin andcreatinine,UACRX X X X X X X
Calcitonin X X X X X X X X
ECGskX X X X X X
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 13Visit 1a2a,b3a4567891011121314801ET
Week of Treatment 640148121620263240485256
Study Day/(Dose number) 0/(1)7/(2)28/(5)56/(9)84/(13)112/(17)140/(21)182/(27)224/(33)280/(41)336/(49)364/ND392/ND
Visit Window (days) ±3±3±7±7±7±7±7±10±14 ±7±7±7
Fasting Visit X XXXXXXXXXXXXXX
Diagnostics (Efficacy)
Liver biopsy XlXmXn
Transient Elastography (Fibroscan)oX XpXrXopXn
FAST Score X
MRI (PDFF and cT1)oXpXorXopXn
HbA1c X X X X X X X X X X X X
Insulin and C-peptide X X X X X X X X
Biomarkers K-18, Pro -C3, ELF, 
Adiponectin, Leptin, NIS4, Ferritin, 
Free Fatty AcidX X X X X X
Patient Reported Outcomes
PGIS X X X
PROMIS Fatigue Short Form 8a X X X
PROMIS Pain Interference Short 
Form 4aX X X
CLDQ-NAFLD X X X
Other
Pharmacogenetic stored samples X
Nonpharmacogenetic stored samples X X X X X
Immunogenicity X X X X X X X X
PK sample for immunogenicity X X X X X X X
PharmacokineticsqX X X
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 14Abbreviations:  ALT = alanine aminotransferase; APTT = activated partial thromboplastin time; AST = aspartate aminotransferase; AUDIT = Alcohol Use 
Disorders Identification Test; BG = blood glucose; BP = blood pressure; CLDQ-NAFLD = chronic liver disease questionnaire –nonalcoholic fatty liver 
disease; cT1 = corrected T1; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; ELF = enhanced live r fibrosis; ET = early termination;
FAST=FibroScan -AST; FIB-4 = fibrosis -4;FSH = follicle -stimulating hormone; HbA1c = hemoglobin A1c; INR = international normalized ratio; IWRS = 
Interactive Web Response System; LH = luteinizing hormone; MRI = magnetic resonance imaging; ND = no dose of study drug; NIS4 = noninvasive score 4; 
PDFF = proton density fat fraction; PK = pharmacokinetics; PGIS = patient global impression of severity; PROMIS = Patient Reported Outcome 
Measurement Information System ; PT = prothrombin time; T2DM = type 2 diabetes mellitus; TSH = thyroid stimulating hormone; UACR = urine albumin -
to-creatinine ratio.
aScreening procedures for Visit 1 and Visit 2 may take more or less time than listed.  Randomization (Visit 3) may occur once all screening procedures have 
occurred, biopsy results received, and the participant qualifies for the study; thus, randomization may occur more or less th an 6 weeks from screening.  
Longer or shorter than 6 weeks from screening will not be considered a pro tocol deviation. All procedures (screening and baseline) need to be completed 
prior to the first dose of study drug.
bParticipants with acceptable previous liver biopsy do not need to attend Visit 2.
cSites should coach and oversee participants self -administer study drug at ever y scheduled visit.  
dStudy drug should be administered at the end of a visit after all other scheduled procedureshave been collected.
eAdditional physical examinations may be performed throughout the study if determined necessary due to participant symptoms.
fDilated fundoscopic examination will be performed between Visit 1 and Visit 2 by an eye care professional (ophthalmologist or optometrist) for T2DM 
patients who have not had a dilated fundoscopic examination in the last 12 months to exclude patients with proliferative diabetic retinopathy, diabetic 
maculopathy , or severe nonproliferative diabetic retinopathy that requires acute treatment.  Follow -up dilated fundoscopic examination should be performed 
when clinically indicated by any adverse event suspected of worsening retinopathy.
gScreening laboratory tests also include serum hepatitis B surface Ag, hepatitis C antibody (Ab), and HIV (human immunodeficiency virus )Ab tests for all 
participants.  Participants treate d for hepatitis C should have a hepatitis C RNA test rather than an antibody test.  
hSerum pregnancy test will be performed by the central laboratory at Visit 1 for women of child -bearing potential.  A urine pregnancy test to beanalyzed 
locally should be given to all women of child-bearing potential at Visit 3 prior to administration of first dose of study drug to confirm lack of pregnancy.
Additional urine pregnancy tests (analyzed locally) should be given to women of child -bearing potential at all other visits beginning at Visit 5 .  Otherurine 
pregnancy test smay be performed locally at the investigator’s discretion if pregnancy is suspected during the study .  
iCollect serum estradiol, FSH, and LH in women whose menopausal status needs to be determi ned.  For participants known to be either premenopausal or 
postmenopausal, these tests do not need to be collected.
jFIB-4 will be calculated by the central laboratory .
kECGs should be collected centrally at Visits 3, 10, 14, and 801, and locally at scre ening and early termination.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 15lParticipants with an acceptable liver biopsy (SeeSection 8.1.1)prior to screening do not need to have an additional screening liver biopsy.   Patients who 
require a screening biopsy should have the biopsy performed once the participant has been found elig ible with respect to all other inclusion and exclusion 
criteria.  
mEnd of treatment liver biopsy may be collected between Weeks 49and 53.Hematology and INR should be measured prior to liver biopsy according to the 
SOA. Additional safety testing may b e performed at the discretion of the investigator .
nEarly termination liver biopsy and all imaging procedures should only be performed on participants who have had at least 9months (36 weeks) study drug 
exposure; for those participants, the biopsy and im aging procedures should be collected within 2 weeks (+/-2weeks) of the last dose of study drug.   
Hematology and INR should be measured prior to liver biopsy according to the SOA.  Additional safety testing may be performed at the discretion of the 
investigator.
oTransient elastography imaging should be collected after at least a 3 -hour fast.  MRI imaging should be collected after at least a 6 -hour fast.  However, 
drinking a small amount of water is acceptable for transient elastography andMRI.  
pBaseline imaging should occur after the liver biopsy confirming eligibility for the study and prior to the first stud y drug administration (Visit 3).  Imaging at 
Week52 will occur up to 2 weeks prior to the last treatment visit (Visit 14)but not after the end-of-treatment liver biopsy .
qPK samples will be collected at these visits at time windows of 1 to 24 hours or 24 to 96 hours postdose, as assigned by IWRS.  Dependent on the time 
windows to which a patient isassigned, the patientmay be required to come to site for PK -specific visits.
rTransient elastography and MRI may occur ±2 weeks of Visit 10 (Week 26) .
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 162. Introduction
2.1. Study Rationale
Tirzepatide is a 39-amino acid synt hetic peptide with agonist activit y at both the 
glucose-dependent insulinotropic polypeptide gastric inhibitory  polypept ide(GIP) receptor and 
the glucagon- like peptide-1 (GLP-1) receptor.  Its structure is based on the GIP sequence and 
includes a C20 fatty  diacid moiety.  It is administered once weekly (QW) by subcutaneous (SC) 
injection.  Treatm ent with tirzepatide results in glucose lowering, wei ght loss, and improve d
metabolic health in patients with type 2 diabetes mellitus (T2DM) (Frias et al. 2018).  The 
beneficial effects of weight loss in pa tients with nonalcoho lic steatohepatit is (NASH) are well -
characterized (Promrat et al. 2010; Vilar-Gomez et al . 2015).  Study  I8F-MC-GPHR (GPHR) 
will invest igate the effects of 52 -week treatment wit h tirzepatidein patients with biopsy-proven 
NASH.  The primary endpo int is NASH resol ution with no worsening of fibrosis, based on liver 
histology.  These data will support dose select ion for Phase3.
2.2. Background
Nonalcoholic Steatohepatitis 
Nonalcoholic steatohepat itis (NASH) is the progressive stageof nonalcoho lic fatty liver disease 
(NAFLD), characterized histologically by the presence of steatosis, lobular inflammat ion, and 
hepatocyte injury (ballooning), wi th or without fibrosis (Chalasani et al. 2018).  Noncirrhotic 
NASH is a silent disease wit h few clinical symptoms and requires a liver biopsy for diagnosis . 
As a consequence, the prevalence of NASH in the general population is unclear, but estimated to 
be between 1.5% and 6.45% (Younossi et al. 2016).  Obesity,T2DM, and dyslipidemia are 
considered important risk factors for NAFLD (Chalasani et al. 2018). The risk of NASH is 
~2-fold higher for patients with diabetes versus patients who do not have diabetes (Williams et 
al.2011; Loomba et al .2012).  The prevalence of NASH in patients with morbid obesi tyhas 
been reported to be 37% ( Machado et al. 2006 ). Those with NASH, especially in the presence of 
fibrosis, are at a higher risk for adverse outcomes, including liver cirrhosis ,liver-related 
mortality, and cardio vascular mortalit y (Angulo et al. 2015 ).  NASH is currently the third -most 
common cause of hepatocellular carcino ma (Van Thiel and Ramadori 2011; Chalasani et al. 
2018).Due to its increasing prevalence, NASH is expected to become the most commo n
indication for liver transplantation in forthcoming years overtaking viral hepat itis (Charlton et al. 
2011).  
There are currently no approved pharmacological therapies available for treatment of NASH. 
The beneficial effects of weight loss on NASH are well-documented (Promrat et al. 2010; Vilar-
Gomez etal. 2015; Chalasani et al . 2018);therefore, currently diet and exercise areconsidered 
the standard treatment for NASH .  For exam ple, losing ≥5% body weight was shown to improve 
hepatic steatosis , induceresolution of NASH, and stabiliz eor improve fibrosis. A ≥10% body  
weight decrease i s associated with improvement sin all features of NASH, including fibrosis
regression (Vilar-Gomez et al. 2015; Chalasani et al. 2018 ). The relationship between NASH, 
increased body  weight, and T2DMprovides a strong rationale to invest igate therapies that induce 
weight loss and improve insulin sensit ivity.  
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 17Tirzepatide
The Phase 2 tirzepat ide clinical trial, I8F -MC-GPGB (GPGB) in participants wi th T2DM wi th 
inadequate glycemic control on diet and exercise alo ne or on a stable dose of met formin 
monotherapy demonstrated dose -dependent reductions in hemoglobin A1c ( HbA1c)and body 
weight.  At Week 26, at doses of 5 mg, 10 mg and 15 mg, the proporti on of subjects wi th 5% 
loss of baseline body  weight was 50.0%, 77.3% and 85.7%, respectively, and the proportion of 
subjects wi th 10% loss of baseline body  weight was 16.8%, 45.5%and 54.3%, respectively .  
Several NASH -related biomarkers from Study  GPGBwere evaluated to explore whether 
tirzepatide may have potential efficacy in NASH (Hartmanet al. 2019).  The following 
biomarkers were included:  alanine aminotransferase (ALT), aspartate transaminase (AST), 
keratin-18 M30 fragment (K-18, apoptosi s marker), Pro -C3 (fibrosis marker, a fragment of the 
NH2-terminal propeptide o f type III procollagen ), and adiponect in (adipokine that protect sthe 
liver from inflammat ion and fibrosis ).  Statistically significant (p<.05) decreases from baseline 
with tirzepatide occurre d in ALT (all doses), AST (1 mg, 5mg, 15mg), K-18 (5mg, 10mg, 
15mg) and Pro- C3 (15 mg).  Decreases were statistically significant for tirzepat ide versus 
placebo in K -18 (10 mg) and Pro -C3 (15 mg), and for tirzepat ide versus dulaglutide in ALT 
(10mg, 15 mg).  Increases in adiponect in with tirzepatide were statist ically significant compared 
with placebo for the 10 -mg and 15 -mg dose groups.  These NASH-related biomarker data in 
patients with T2DM, al ong with the weight loss findings, support the hy pothesis that tirzepat ide 
may have beneficial effects in NASH (Hartmanet al. 2019).
Additional nonclinical and clinical trial data are summarized in the Investigator’s Brochure (IB).
2.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits , risks, serious adverse events (SAEs),
and reasonably ant icipated adverse events (AEs) of tirzepatideare to be found in the IB.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 183. Objectives and Endpoints
Objectives Endpoints
Primary
To demonstrate that ti rzepatide 5 mg, 10 mg or 
15mg administered SC QW is superior to 
placebo for NASH resol ution with no 
worsening of fibrosis at Week 52.Proportion of participants cl assified wi th 
absence of NASH with no worsening of 
fibrosis on liver histology  as defined in Sect ion 
8.1.1.
Secondary
To demonstrate that ti rzepatide 5 mg, 10 mg or
15 mg administered SC QW is superior to 
placebo at Week 52 for: 
From baseline:
Regressio n of fibrosis with no worsening of 
NASHProportion of participants wi th ≥1 point 
decrease in fibrosis stage with no 
worsening of NASH on liver histology
Prevention of fibrosis progression Proportion of participants wi th ≥1 point 
increase in fibrosis stage on liver histology
Decreasing NAS by  ≥2 points Proportion of participants that achi eve a 
≥2point decrease in NAS on liver 
histology, with ≥1 point reducti on in at 
least 2 NAS components (steatosis, 
hepatocellular ballooning, lobular 
inflammat ion)
Decreasing liver fat conte nt Mean abso lute change in liver fat content 
by MRI-PDFF
Decreasing body  weight Mean change in body  weight
Tertiary/Exploratory  
Investigate the effect of tirzepat ide 5 mg, 10 
mg or15 mg SC QW versus placebo at various 
time points for: From baseline: 
Additional histological measures Mean change in the liver histo logy score 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 19for:  
oExpanded ballooning score
oExpanded portal inflammat ion score
oExpanded fibrosis stage 1 scores
oMallory-Denk body  score
oGlycogenosis score
Liver inflammat ion and fibrosis measured 
by MRIMean change in extracellular hepat ic water 
content m easured by  iron-corrected T1 
imaging (cT1, in ms) by  MRI
Liver stiffness measured by TE Mean change in liver stiffness (in kPa) 
measured by TE
Liver enzymes and serum bio markers of 
NASH and fibrosisMean change in ALT, AST, GGT, K -18, 
Pro-C3, ELF, FIB -4, Adiponectin, Leptin, 
and Ferritin
Insulin sensit ivity Mean change sinfasting insulin and
HOMA-IR
Decreasing waist circumference Mean change in waist circumference 
(centimeters)
PROs Change in:  
oPROMIS Fatigue short form 8a v1.0 
score
oPROMIS Pain Interference short form 
4a v1.0 score
oChronic Liver Disease Quest ionnaire 
for nonalcoho lic fatty liver disease total 
and domain scores
oPatient Global Impression of Severity 
(PGIS) score
NASH reso lution NASH reso lution based on overall 
assessment of histology  by patho logists 
Decreasing NAFLD Act ivity Score (NAS) Mean change in NAS on liver histology
Decreasing steatosis, hepatocellular 
ballooning or lobular inflammat ionMean change in the liver histo logy score 
for: 
oSteatosis
oHepatocellular ballooning
oLobular inflammat ion
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 20Decreasing steatosis, hepatocellular 
ballooning ,or lobular inflammat ion by ≥1 
pointProportion of participants that achi eve a ≥1 
point improvement in the liver histo logy 
score for:  
oSteatosis
oHepatocellular ballooning
oLobular inflammat ion
Decreasing fibrosis stage Mean change in fibrosis stage on liver 
histology
Regressio n of fibrosis with no worsening o f 
NASHProportion of participants wi th: 
o≥2 point decrease in fibrosis stage, and 
no worsening of NASH on liver 
histology
Prevention of progression to cirrhosis Proportion of participants cl assified wi th 
cirrhosis (F4) on liver histolog y
Resolution of fibrosis Proportion of participants cl assified wi th 
absence of fibrosis on liver histology
Relative decreases in liver fat content Mean percentage change in liver fat content 
by MRI-PDFF 
Decreasing liver fat content Mean abso lute change in liver fat content 
by MRI-PDFF
Decreasing liver fat content by  ≥30% from  
baselineProportion of participants that achi eve a 
≥30% relat ive decrease in liver fat content 
by MRI-PDFF
Relative decreases in body  weight Mean percentage change in body  weight
Decreasing body  weight by  5%, 10%, 15%, 
and 20%Proportion of participants that achi eve 
≥5%, ≥10%, ≥15%, or ≥20% decrease in 
body weight
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; ELF = enhanced liver fibrosis; 
FIB-4 = fibrosis-4; GGT = Gamma-glutamyl transferase ; K-18 = keratin-18 M30 fragment ;HOMA-IR = 
Homeostatic Model Assessments for Insulin Resistance ; MRI = magnetic resonance imaging; MRI -PDFF = 
magnetic resonance imaging –proton density fat fraction; ms = millisecond; NAFLD = nonalcoholic fatty liver 
disease; NAS = NAFLD activity score; NASH = nonalcoholic steatohepatitis; PGIS = Patient Global Impression 
of Severity; PRO = patient reported outcome; PROMIS = Patient Reported Outcome Measurement I nformatio n 
System;SC = subcutaneous; TE = transient elastography ; QW = once weekly.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 214. Study Design
4.1. OverallDesign
Study GPHR is a Phase 2, m ulticenter, randomized, double- blinded, placebo -controlled study  
that will invest igate the effects of treatment with t irzepatide 5 mg,10 mg and 15 m g SC QW 
compared with placebo on NASH resolut ion with no worsening of fibrosis in patients with 
biopsy-proven NASH and fibrosis, with or without T2DM .  
Four intervention groups will be studied:  
Tirzepatide 5 mg SC QW, ini tially 2.5 m g SC QW for 4 weeks then 5 mg SC QW
Tirzepatide 10 mg SC QW, ini tially 2.5 m g SC QW then dose escalated by 2.5mg every 
4weeks unt il target dose is reached
Tirzepatide 15 mg SC QW, ini tially 2.5 m g SC QW then dose escalated by 2.5mg every 
4weeks unt il target dose isreached
Placebo
All participants will receive diet and physical act ivity counseling throughout the study . 
Study GPHR will consist of 3 periods:  
Screening (Visit s 1 and 2)
Treatment (Visits 3 to 14)
o4-to 20-week dose escalat ion (4-week for 5 mg group, 12-week for 10 mg group, 
20-week for 15 mg group)
o32-to 48-week maintenance ( 48-week for 5 mg group, 40-week for 10 mg group, 
32-week for 15 mg group)
Safety follow-up (4 weeks post -treatment, through Vi sit 801)
The maximum total duration of the combined treatment periods is 52 weeks.  
The approximate maximum total duration of study  participation for each participant, including 
screening and post -treatment follow-up periods, is 68 weeks.  Some participants may re quire 
additional follow-up after V801 f or evaluati on of treatment-emergent antidrug antibodies ( ADA). 
Enrichment Strategy
Participants with biopsy-proven NASH will be enrolled into this study .  The study  population 
will be enriched for participants who ha ve T2DM, such that 40 %to 65% of the total study  
population will consist of participants with NASH who have also been diagnosed wi th T2DM.  
The other 35 %to 60% of the study population will consist of participants with NASH who do 
not have T2DM.
Participant Visit Scheme
Study participants will undergo screening assessments and procedures, double -blinded treatment 
with investigational product or placebo, and a post-treatment safet y follow-up visit.  Assessments 
and procedures to be conducted in eac h treatment period are described in the Schedule of 
Activities (SoA; Section1.3), and in Study  Assessments and Procedures (Section 8).
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 22Screening procedures will be performed at Visit 1 through Visit 2.  All screening procedures 
must be completed prior to or at Visit 3.  These measurements will occur prior to randomizat ion 
and prior to the first administration of study  drug.  
Participants with a qualifying liver biopsy performed within 6months of screeni ng who m eet the 
other required inclusio n and exclusio n criteria can parti cipate in the study  after evaluat ion of the 
histology by 2central pathologists with experience in NASH to confirm presence of NASH and 
the study-specific histological inclusio n criteria.  Visit 2 will be omitted for these participants.  
Participants withouta qualifying liver biopsy will undergo assessments of their controlled 
attenuation parameter (CAP) and liver stiffness measurement (LSM) at Visit 1 using transient 
elastography  (TE)(refer to Section 5.1, inclusion criterion 5b for further detail) to determine if 
they havea high probabilit y of fatty liver disease wi th fibrosis.  Participants m eeting prespecified 
criteria for a high probabilit y of fatty liver disease with fibrosis by TE will undergo a liver 
biopsy at Visit 2 to assess study  eligibility, provided they meet all other requi red inclusion and 
exclusion criteria.  Liver biopsies will be eval uated by 2central pathologists with experience in 
NASH prior to Visit 3 to confirm presence of NASH and study -specific histological inclusion 
criteria.  
Participants will be treated for a total of 52 weeks.  Tirzepat ide will be dose escalated as 
illustrated in the study  schema (Section 1.2).  
Participants will remain in the study  for a 4-week safet y follow-up period, during which 
participants are off study  drug.  
4.2. Scientific Rationale for Study Design
Study GPHR is a Phase 2 study  designed to examine the efficacy and safet y of QW tirzepatide 
compared with placebo in patients with biopsy -proven NASH and fibrosis .  Body weight and 
NASH bio marker data from the tirzepatide Phase 2 study  in T2DM ( GPGB; Section 2.2) 
provide a strong rationale for development of tirzepatide as a potential treatment for NASH .
Inclusion of a placebo comparator in Study  GPHR will allow for a direct comparison of the 
safety and efficacy o f tirzepatide in patients with NASH over a 12- month time period.  The 
currently reco mmended treatment for NASH is diet and exercise in order to reduce body 
weight.  All patients will receive diet and exercise counseling (See Appendix 6, Section 10.6), 
thus placebo pati ents will be receiving the recommended treatment for NASH.  Although some 
Phase 2 studies o f other com pounds being invest igated for treatment of NASH have had 
treatment durations less than 12months, a treatment duration of 52 weeks was chosen because 
of the need for a 20 -week dose escalat ion period for the 15 m g dose of ti rzepatide.  This slow 
dose escalat ion approach was chosen to minimize gastrointestinal (GI) side effectsof 
tirzepatide, which werecommon in the Phase 2 T2DM study that included a shorter dose 
escalation period (6 weeks to reach 15 mg SC QW) .  Thus, the 52 -week treatment period will be 
sufficient to comparethe effects of tirzepatide and placebo to resolve NASH.  Several 
noninvasive methods to evaluate NASH and fibrosis , utilizing serum biomarkers and imaging 
modalities, have been included in the study  with the objective of developing future alternat ives 
to liver biopsy  fordiagnosis of NASH and evaluation of treatment effects of tirzepat ide in 
patients with NASH.  The data from this study  will inform the decisio n of whether to continue 
evaluation of tirzepatide in Phase 3 studies for treatment of NASH.  
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 234.3. Justification for Dose
Tirzepatide doses of 5 mg, 10 mg and 15 m g administered SCQW will be evaluated in this 
study.  These doses and associated escalat ion schemes were selected based on assessment of 
safety, efficacy (weight loss benefit), and GI tolerabilit y data followed by exposure response 
modeling of data in T2DM patients in Phase 1 and 2 studies.  Dosing algorithms starting at a low 
dose of 2.5 mg acco mpanied by dose escalat ion of 2.5 m g increments every  4weeks woul d 
permit time for development of tolerance to GI events and are predicted to min imize GI 
tolerability concerns.  
The tirzepatide 5 mg, 10 mg,and 15 mg doses provided clinically relevant wei ght loss relative to 
placebo in the 26-week Phase 2 Study GPGB.  The percent of patients achieving ≥10% body  
weight loss wasprogressively higherwith increasing dose levels .  In contrast, the proportion of 
patients with gastrointestinal adverse events was progressiv ely higher wi thincreasing dose levels
in the Phase 2 study .  Thus, inclusio n of these3 doses in Study GPHR will enable assessment of
dose-response and balance between efficacy  and tolerabili ty.  The NASH bio marker results from 
Study GPGBdemonstrated statistically  significant differences co mpared with placebo for most 
of the NASH bio markers wit h the 10 mg and/or the 15 m g doses.
The selected dose sand escalat ion schemeswill enable further evaluat ion of benefit/risk 
considerations for the 5 mg, 10 mg,and 15 mg doses of ti rzepatide.  
4.4. End of StudyDefinition
End of tri al is defined as the last visit or the last scheduled procedure shown in the SoA for the 
last participant.
A participant is considered to have co mpleted the study  if he/she has co mpleted all phases of the 
study including the last visitor the last scheduled procedure shown in the S oA.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 245. Study Population
Prospective approval o f protocol deviations to recrui tment and enro llment criteria, also known as 
protocol waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all o f the following criteria apply:
Age
1.Participant must be 18 to 80years of age (inclusive), at the time of signing the informed 
consentform(ICF).
Type of Participant and Disease Characteristics
2.Body mass index (BMI) ≥27 kg/m2and ≤50 kg/m2
3.For participants wi th T2DM:  
a.HbA1c ≤9.5% at tim e of screening
b.Treated with diet and/or exercise, or treated with oral antihyperglycemic 
medication (metformin, sulfo nylureas, SGLT -2 inhibitors, DPP-4inhibitors, 
and/or TZDs) with
i.Stabledose for at l east 3 months before screening (6 months for TZDs)
OR
ii.Stable dose for at l east 3 months before baseline liver biopsy , if baseline 
liver biopsy was performed prior to screening (6 months for TZDs)
c.For participants treated with a DPP -4 inhibitor, the medicat ion must be 
discontinued prior to randomizat ion (See Section 5.2)
4.For participants wi thout diagnosed T2DM: 
a.HbA1c <6.5% at screening
b.Fasting glucose <7.0 mmo l/L (126 m g/dL)
5. Diagnosis of NASH by liver biopsy:
a.Individuals may  be eligible if they have had a liver biopsy no tmore than
6months prior to screening. The liver biopsy slides need to be available for 
review,and presence of definite NASH according to the NASH Clinical Research 
Network (CRN) classificat ion needs to be confir med by 2sponsor-designated
central pathologists.  All study -specific histol ogical inclusion criteria must be met
andconfirmed by  the central  pathologists.
b.Individuals for whom (i.)no liver biopsy has been performed wit hin 6months of 
screening, (ii.)the previously performed liver biopsy is not of adequate qualit y, or 
(iii.)the previously  performed liver bi opsy is not available for review are required 
to undergo a baselineliver biopsy as part of screening to determine definite 
NASH according to the NASH CRN classificat ion prior to randomizat ion. To be 
CONFIDENTIAL  Protocol I8F -MC-GPHR( d) 
LY3298176  25 eligible for a liver biopsy at baseline, these individuals need to meet the following criteria:  
i. T2DM or at least 1 of the following weight -related comorbidit ies:  
1. Central obe sity ( waist circumference ≥35 inches [89 cm]  for 
women; ≥ 40 inches [102 cm] for men)  
2. Impaired fasting glucose (≥ 100 mg/dL [5.56 mmol/L ]) 
3. Elevated fasting triglycerides ( treated and/or ≥150 mg/dL 
[1.7 mmol/L ]) 
4. Hypertension ( treated and/or systolic blood pre ssure ≥130 mm Hg 
or diastolic blood pressure ≥85 mm Hg)  
5. Low high-density lipoprotein cholesterol  (treated and/or <50 
mg/dL [1.29 mmol/L] for women or <40 mg/ dL [1.03 mmol/L] for 
men)  
ii. CAP >2 88 dB/m by TE, or higher at the discretion of the investigator  
iii. LSM >7.6 kPa and < 20 kPa by TE 
iv. AST > 23 U/L 
v. FibroScan-AST ( FAST ) score >0.35 (see Section 8.1.3.3.1 for details)  
When TE is of insufficient quality ( See definitions in S ection 8.1.3.3 ) or LSM is 
>7.1 but ≤ 7.6 kPa and/or the CAP is >283 but ≤ 288 dB/m , following criteria 
may be used:   
i. T2DM or  at least 2 weight -related comorbidities (as defined  above ) 
ii. Fibrosis -4 (FIB-4) >1.3 and <3.2 
iii. AST > 23 U/L 
6. NAFLD Activity Score (NAS) ≥4 with ≥1 point  for each component  
7. Fibrosis stage  2 or 3 according to the NASH CRN scoring system  
8. Stable body weight (≤5% body weight change) for at least 3 months .  For participants 
entering the study with a liver biopsy done between 3 to 6 months from the screening 
visit, body weight must be stable (<5% body weight change) for the period of time 
between the biop sy and the screening visit.  
9. Participants currently treated with vitamin E (≥400 IU QD)  or TZDs for NASH need to 
remain on treatment during the study, and need to be on a stable dose for at least 
6 months prior to screening or need to be off treatment for at least 6 months prior to 
screening  
10. Participants with a documented history of Gilbert’s syndrome may be enrolled if the direct bilirubin is within normal referen ce range 
11. Individuals who are, in the investigator’s opinion, well -motivated, capable, and wi lling 
to:  
a. Self-inject study drug or have the assistance of a trained individual who will inject 
the study drug  
b. Undergo baseline and endpoint liver biopsies  
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 26c.Maintain a study  diary, as required for this protocol
Sex
12.Males and females will be eligible for this study
a.Contraceptive use by men or women should be consistent with local regulat ions 
regarding the methods of contraception for those participat ing in clinical studies
b.Male parti cipants:  
i.Men with partners of child -bearing potential, for the duration of the study  
and for 5 half -lives of the study  drug plus 90 days after the last dose of 
study drug (corresponding to 4months), will either remain abstinent (if 
this is their preferred and usual lifest yle) or use condoms plus 1additional 
highly effective (less than 1% failure rate) method of contraception (such 
as combinat ion oral contraceptiv es[estrogen and progestogen containing 
hormonal contracepti on associated with inhibition of ovulation], implanted 
contraceptives or intrauterine device) or an effective method of 
contraception (such as male or female condo ms with spermicide, 
diaphragms wi th spermicide or cervical sponges). Men and their partners 
may choose to use a double-barrier method of contraception .(Barrier 
protection methods wi thout concomi tant use of a spermicide are not an 
effective or acceptable method. Thus, each barrier meth od must include 
use of a spermicide. It should be noted however, that the use of male and 
female condo ms as a double barrier method is not considered acceptable 
due to the high failure rate when these barrier methods are combined). 
Periodic abstinence (e.g., calendar, ovulat ion, symptothermal, 
postovulat ion methods), declarat ion of abstinence just for the duration of a 
trial, and withdrawal are not acceptable methods of contraception.
ii.Men should refrain fro m sperm donation for the duration of the study  and 
for 5 half-lives of the study  drug plus 90 day s after the l ast dose of study  
drug(corresponding to 4 months ).
iii.Men who are in exclusively same sex relat ionships (when it is their 
preferred and usual lifest yle) are not required to use contraception.
c.Female participants:
i.Women of child- bearing potenti al who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same sex 
relationship (as part of their preferred and usual lifest yle) must agree to
either remain abstinent or stay in a same sex relat ionship wit hout sexual 
relationships wit h males. Periodic abstinence (e.g., calendar, ovulat ion, 
symptothermal, postovulat ion methods), declarat ion of abstinence just for 
the duration of a trial, and wit hdrawal are not acceptable methods of 
contraception.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 27ii.Otherwise, women of child -bearing potential participat ing must agree to 
use 2 forms of effect ive contraception, where at least one form is highly 
effective (less than 1% failure rate) ,for the entirety of the studyand for 30 
days thereafter.
A.Women of child- bearing potenti al participating must test negative 
for pregnancy  prior to initiation of treatment as indicated by  a 
negative serum pregnancy test at the screening visit fo llowed by a 
negative urine pre gnancy test within 24 hours prior to exposure. 
B.Two forms of effect ive contraception, where at least one form is 
highly effective, (such as combined [estrogen and progesterone 
containing] hormonal contracept ion associated with inhibition of 
ovulation, implanted contraceptives or intrauterine devices) will be 
used.  Effect ive contraception (such as male or female condo ms 
with spermicide, di aphragms with spermicide or cervical sponges) 
may be used as the second therapy .  Barrier protectio n methods 
without concomitant use of a spermicide are not a reliable or 
acceptable method. Thus, each barrier method must include use of 
a spermicide (i.e., condom  with spermicide, diaphragm with 
spermicide, female condo m with spermicide) .It should be noted 
that the use of male and female condo ms as a double barrier 
method is not considered acceptable due to the high failure rate 
when these methods are combined.
iii.Women not of child -bearing potential may part icipate and include those 
who are:  
A.infertile due to surgical steril ization (hysterectomy, bilateral 
oophorectomy , or tubal ligation), congenital ano maly such as 
mullerian agenesis; or
B.postmenopausal –defined as eit her
a.A woman at least 40 years of age with an intact uterus, not 
on hormone therapy , who has cessat ion of menses for at 
least 1 year without an alternative medical cause, AND a 
follicle-stimulating hormone >40 m IU/mL; or
b.A woman 55 years of age or older not on horm one therapy , 
who has had at least 12 months of spontaneous 
amenorrhea; or
c.A woman at least 55 years of age with a diagnosi s of 
menopause prior to starting hormone replacement therapy.
iv.Must not be breastfeeding
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 28Informed Consent
13.Capable of giving signed informed consent as described in Appendix 1 (Section 10.1.2),
which includes co mpliance wit h the requirements and restrictions listed in the ICF and in 
this protocol .
5.2. Exclusion Criteria
Participants are excl uded from  the study  if any of the fo llowing criteria apply:
Medical Conditions
14.Alcohol consumpt ion >14 units/week for women and >21 units/week for men
15.Fibrosis stage s 0and 1according to the NASH CRN scoring system on liver biopsy
16.Cirrhosis (fibrosisstage 4) 
17.Platelet count <150,000/mm3
18.Evidence of other form s of chronic liver disease:
a.Alcoholic liver disease
b.Hepatitis B as defined by presence of hepa titis B surface antigen (HBsAg)
c.Hepatitis C as defined by presence of hepat itis C virus (HCV) RNA or posit ive 
hepatitis C antibody (anti-HCV).  Participants treated for hepat itis C (and 
diagnosed as cured) must have an RNA test at screening and also be RNA 
negative for at least 3 years prior to screening in order to be eligible for the study
d.Primary biliary cholangitisas defined by  the presence of at least 2 of the 
following:
i.Biochemical  evidence of cholestasis based mainly  on alkaline phosphatase
(ALP)elevation
ii.Presence of ant imitochondrial ant ibody 
iii.Historical evidence of nonsuppurat ive destructive cho langitis and 
destruction of interlobular bile du cts
e.Evidence of autoimmune liver disease as defined by  compatible liver histology
f.Primary sclerosing cho langitis
g.Current drug -induced liver disease as defined on the basis o f typical exposure and 
history
h.Suspected or proven liver cancer
i.Any other ty pe of liver disease other than NASH
19.Transferrin saturation >50%, except when it has been demonstrated that a diagnosis of 
hemochro matosis has been excluded by genet ic testing and when a previous liver biopsy 
has demonstrated no evidence of iron overload
20.Clinical evidence o f hepatic decompensation as defined by the presence of any o f the 
following abnorm alities:
a.Serum albumin < 3.5g/dL
b.International normalized ratio (INR)>1.3
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 29c.Direct bilirubin > upper limit of normal (ULN) at screening
d.History of esophageal  varices, ascites ,or hepatic encephalopathy
21.ALT or AST levels >5 times upper limit of normal ( ULN)at screening
22. ALP≥1.5 the ULN at screening
23.Inability to safely  obtain a liver biopsy
24.History of biliary diversio n
25.Known posit ive for human immunodeficiency virus infect ion
26.Active, serious medical disease wit h likely life expectancy <5 years
27.Active substance abuse including oral, inhaled or inject ion drugs in the y ear prior to 
screening
28.Use of marijuana wit hin 3 months of enrollment and unwilling to abstain from marijuana 
use during the trial.  Patients should also refrain from use of cannabidiol (CBD)oil for the 
duration of the study  
29.Any current or hi storical condition (for example , diagnosed eating disorder or other 
psychiatric disorder) that, in the opinion o f the investigator, may preclude the participant
from following and com pleting the protocol
30. Other condition which, in the opinio n of the investigator, would impede co mpliance or 
hinder complet ion of the study
Diabetes-Related
31.Uncontrolled T2DM defined as HbA1c >9.5% within 3 mo nths prior to screening
32.Type 1 diabetesmellitus (T1DM) , latent autoimmune diabetes in adults, history of 
ketoacidosis ,and/or hy perosmolar state/coma
33.Patients with T2DM who have a history  of proliferative diabet ic retinopathy , diabetic 
maculopathy or severe nonpro liferative diabet ic retinopathy that requires acute treatment.  
Patients with T2DM shoul d have had a dilated fundoscopic exam, performed by an 
ophthalmo logist or optom etrist, within 12 m onths of screening .
Obesity-Related
34.Prior (within 5 years) or pl anned (during the study) surgical treatment for obesit y 
35. Obesity which is induced by other endocrin e disorders ( such as Cushing’s syndrome or
Prader-Willi syndrome)
Other Medical Conditions
36. Renal impairment measured as est imated glo merular filtration r ate (eGFR) 
<30mL/min/1.73 m2, calculated by  chronic kidney disease -epidemiology as determined 
by central laboratory  during screening ; for patients on m etformin, eGFR <45 
mL/min/1.73m2(or lower than the country -specific thresho ld for using the prescribed 
dose of met formin per local label)
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 3037. Known clinically  significant gastri c emptying abnorm ality (for example, severe diabet ic 
gastroparesi s or gastri c outlet obstructi on) or chronically take drugs that direct ly affect 
gastrointestinal mot ility
38. History of chronic or acute pancreatit is. A patient with a history of acute pancreat itis 
caused by  gallstones may  be included in the study  if the pat ient had a cho lecystectomy to 
resolve the problem
39. Uncontrolled hypertens ion (systolic blood pressure ≥160 mmHg and/or diastolic blood 
pressure ≥ 100 mmHg).  For parti cipants wi th uncontrolled hypertensio n at the screening 
visit, antihypertensive medicat ion may be started and blood pressure must meet the 
protocol criterion for hypertensio n control by  the randomizat ion visit
40.Uncontrolled inflammatory  bowel disease (IBD) and/or not on stable therapy  for the last 
3 months or clinically symptomat ic IBD with C -reactive protein >4 mg/L. 
41.Any medical condit ion that, in the opinio n ofthe investigator, may increase the risk of 
complications related to a liver biopsy (e.g., a known coagulopathy )
42. Any of the fo llowing cardiovascular conditions within 6 months prior to screening : 
a.acute myocardial infarction(MI), 
b.cerebrovascular accident (stroke), 
c.unstable angina, or 
d.hospitalization due to congestive heart failure (CHF)
43.New York Heart Associat ion Functional Classification IV CHF
44.Have a serum calcitonin o f 
(a) ≥20 ng/L at Visit 1 if eGFR is ≥60 mL/min/1.73 m2
(b) ≥35 ng/L at Visit 1 if eGFR is <60 mL/min/1.73 m2
45.Have a known self or family  history (first-degree relat ive) of mult iple endocrine 
neoplasia type2A or type2B, thyroid C-cell hyperplasia, or m edullary thyroid carcinoma
(MTC)
46.Evidence of untreated hypothyroidism or hyperthyroidism based on clinical and 
laboratory  evaluation.  Individuals on a stable dose of thy roid replacement therapy  for at 
least the prior 3 months who are clinically  euthyroid and who are anticipated to remain 
on this dose throughout the trial period may be eligible if they  meet the other criteria.
47. History of an active or untreated malignancy  or are in remission from  a clinically 
significant malignancy  (other than basal or squamous cell skin cancer, in situ carcinomas 
of the cervix, or in situ prostate cancer ) for less than 5 y ears
48. Any other condit ion (for example, hypersensit ivity) that is a contraindicat ion to GLP-1
receptor agonist
49. Atransplanted organ (corneal transplants [keratoplast y] allowed) or awai ting an organ 
transplant
50. Any hematol ogical condition that may interfere with HbA1c measurement (for example, 
hemolytic anemias, sickle cell disease)
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 31Prior/Concomitant Therapy
51. Have used insulin for treatment of diabeteswithin the pri or year.  However, short -term 
use of insulin for acute conditions is allowe d (≤14 days) in certain situat ions, such as 
during a hospitalizat ion or perioperatively ( See Section 6.5.1.2)
52.Current or previous (within 3 months of screening) use of GLP-1receptor agonists or any 
history of allergies to these medicat ions.
53. Use of drugs associated with hepatic steatosis ( e.g.,amiodarone, methotrexate , 
tamoxifen) for more than 2 week s in the 3 monthsprior to screening .  If the use of such 
drugs is anticipated to be medically necessary  within the next y ear, the patient should 
also be excluded.
54. Current use of medicat ion associated with weight gain, except when on stable dose for at 
least 3 months prior to screening and remaining on stable dose during the study
55. Receiving or hav ingreceived(within 3monthsof screening) chronic (>2 weeks) 
systemic glucocortico id therapy (excluding topical, intra -ocular, intranasal, intra -
articular, or inhaled prepar ations) or have evidence of a significant active autoimmune 
disease(such as systemic lupus erythematosus or rheumatoid arthrit is) that has required 
(within the last month) or is likely to require ( in the opinion o f the investigator)
concurrent treatment with systemic glucocortico ids (excluding topical, intra -ocular, 
intranasal, intra -articular or inhaled preparations) in the next 12 months
56.Use of medicat ionsor alternative rem edies(within 3months prior to screening; 
prescribed or o ver-the-counter) int ended to promote weight loss.  These include, but are 
not limited to: Saxenda [liraglut ide 3.0 mg] , Alli®/Xenical® [orlistat] , Meridia® 
[sibutramine] , Acutrim® [phenylpropano lamine], Sanorex® [mazindo l], Apidex® 
[phentermine] , BELVIQ® [lorcaserin] , Qsymia™ [phentermine/topiramate 
combination], Contrave® [naltrexone/bupropion] .  (See also Inclusio n criteria #9)
57.Unwillingness to discont inue over-the-counter (herbal) medication that ,in the opinio n of 
the investigator,can interfere with t he study
58.Active and chronic use o f anticoagulants (other than aspirin or nonsteroidal ant i-
inflammatory  drugs [NSAIDs]) that ,in the opinio n of the invest igator,increasesthe risk 
of severe bleeding during the liver biopsy .
Prior/Concurrent Clinical Study Experience
59. Are currently enrolled in any other clinical study  involving an invest igational product or 
any other ty pe of medical research judged not to be scient ifically or medically co mpatible 
with this study
60. Have participatedwithin the last6monthsin a clinical study  involving an invest igational 
product
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 32Other Exclusions
61. Investigator site personnel direct ly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally  adopted
62.Lilly emplo yees
63.Unwilling or unable to comply wit h study diary or questionnaire completion required to 
record data from the participant
5.2.1. Rationale for Select Exclusion Criteria
Marijuana should not be used during the study  because the re are mixed data on its effect on the 
liver, particularly in NASH.  Use of CBD oil is also discouraged because there are data 
indicating that it can raise liver enzymes, which could result in unnecessary fo llow up tests. 
5.3. Lifestyle Considerations
Medical staff will provide weight management counseling per the SoA (Section 1.3), which will 
include reco mmendations on diet and physical activit yaccording to site programs.  Based on the 
counseling provided by the site personnel, participants should fo llow a healthy lifestyle plan 
throughout the course of the study .  Diet and physical  activity counseling may be reviewed 
throughout the study  as needed. Appendix 6 (Section 10.6)provides suggested diet and physical 
activityrecommendations for sites that do not have programs and that may be modified as 
appropriate locally .  
Patients will report to the clinical research site for safet y assessments and will remain in the 
clinic until all procedures for that visit are complete and the invest igator has deemed it safe to 
release the pati ent from the clinic.  There will be no inpatient stays.  In addition, patients will 
report to the clinical research site for pharmacokinetic ( PK)-specific visits.
Meals/Diet –Patients will fast for at l east 8 hours overnight prior to each outpatient visit where 
fasting samples are drawn or for at least 8 hours when weight measurements are taken.
Alcohol –Alcohol will not be permitted 8 hours prior to the study site visits, until the patient 
has been discharged from the clinical research site.
Blood Donation –Study part icipants should be instructed not to donate blood or blood products 
during the study  and for 8 weeks fo llowing the study .
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical studybut are 
not subsequently randomly  assigned to study  interventiondue to not m eeting inclusion and/or 
exclusion criteria.A minimal set of screen failure informat ion is required to ensure transpare nt 
reporting of screen failure participants to meet the Conso lidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries fro m regulatory authorities. 
Minimal informat ion includes demography, screen failure details, eligibilit y criteria, and any 
SAE.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 33Individuals who do not meet the criteria for participation in this study  (screen failures) may be 
rescreened only once at the discret ion of the investigator .  Before rescreening is performed, the 
patient must sign a new ICF and receive a new ident ification number.  If, in the opinio n of the 
investigator, an ineligible lab test result is the result of an error or extenuating circumstance, then 
that parameter c an be retested once without the patient having to be rescreened.
Patients who di d not meet eligibilit y criteria for liver bi opsy or the histological inclusio n criteria 
based on liver biopsy results may not be rescreened.
Patients whose screening HbA1c is outside of inclusi on/exclusion criteria may be rescreened 
3months after adjust ments in allowed glucose-lowering medications are m ade.  While patients 
on stable doses of DPP -4 inhibitors are eligible for study  entry, treatment with DPP-4 inhibitors 
needsto be discont inued prior to randomizat ion. For patients treated with a DPP -4 inhibitor and 
whose HbA1c is ≤8% at the screening visit, this medicat ion must be discontinued with no repeat 
screening required; the rando mization visit should occur approximat ely3 months after the 
screening visit and discont inuation of the DDP -4 inhibitor so that a new baseline HbA1c may be 
established at randomizat ion.  For patients treated with a DPP -4 inhibitor and whose HbA1c is 
>8% but ≤9.5% at the screening visit, this m edication must be discont inuedfor eligibilit y into 
the study, but a rescreening laboratory  collectionwill be required to ensure that the HbA1c is 
≤9.5% pri or to the liver biopsy (Visit 2).
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 346. Study Intervention
Study intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo,or medical device (s)intended to be administered to a study  participant according to the 
study protocol.
6.1. Study Intervention(s) Administered
The following table shows the randomized study  interventions for the entire study.  All doses 
will be administered SC QW using a single -dose prefilled syringe.
Treatment Group Treatment Period Interval
Weeks
0to3Weeks
4to7Weeks
8to11Weeks
12 to 15Weeks
16 to 19Weeks
20 to52
15 mg tirzepatide 2.5 mg 5 mg 7.5 mg 10 mg 12.5mg15 mg
10 mg tirzepatide 2.5 mg 5 mg 7.5 mg 10 mg
5 mg tirzepatide 2.5 mg 5 mg
Placebo
The sponsor will provide t irzepatide and placebo inprefilled sy ringes.  These will be dispensed 
via an interactive web- response system (IWRS).  Prefilled syringes will be packaged in cartons 
to be dispensed.  Clinical trial materials will be labeled according to the country’s regulatory  
requirements.  
The actual time of dose administrations will be transcribed in patient diariesand provi ded to the 
sponsor.
The invest igator or designee is responsible for the fo llowing:  
Explaining the correct use of the invest igational agent to the participant
Verifying that instructi ons are fo llowed properly
Maintaining accurate records of invest igational product dispensing and co llection as well as 
records of interruptions in study  drug administrati on
Instructing the participant to discard all used syringes for tirzepat ide in a closeable, 
puncture-resistant container and dispose according to local regulat ions
6.1.1. Medical Devices
Tirzepatide and matching placebowill be provided in prefilled syringe s.  
6.2. Preparation/Handling/Storage/Accountability
1.The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervention received and any discrepancies are 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 35reported and resolved before use of the study  intervention.  Refer to the study  drug label 
for specific storage conditions.  
2.Only participants enro lled in the study  may receive study  intervention and only 
authorized site staff may  supply or administer study  intervention. All study intervention 
must be stored in a secure, environmenta lly controlled, and mo nitored (manual or 
automated) area in accordance wit h the labeled storage conditions with access limited to 
the investigator and authorized site staff.
3.The invest igator, institution, or the head of the medical inst itution (where appli cable) is 
responsible for study  intervention accountabilit y, reconciliat ion, and record maintenance 
(that is:receipt, reconciliat ion, and final disposit ion records).
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a double -blind study .  Patients will be stratified at randomizationbased on T2DM status
(Yes or No) and the region (Japan, US including Mexico, and Europe including Israel) .  
Stratificat ion will ensure the number of pat ients in each strat umwill be balanced across different 
treatment arms.
To preserve the blinding of the study , a minimum number of Lilly  personnel  will see the 
randomization table and treatment assignments before the study  iscomplete.
Emergency  unblinding for AEs m ay be perform ed through the IWRS, which m ay supplem ent or 
take the place of emergency  codes generated by  a computer drug -labeling system.  This option 
may be used ONLY if the participant’swell-being requi res knowledge of theparticipant’s
treatment assignment.  All  calls result ing in an unblinding event a re recorded and reported by  the 
IWRS.
If an investigator,site personnel performing assessments, or participant is unblinded, the 
participant must be discontinued from the study.  In cases where there are ethical reasons to have 
theparticipant remain in the study , the investi gator must obtain specific approval from a Lilly  
clinical research physician (CRP) or clinical research scient ist (CRS) for theparticipant to 
continue in the study .
In case of an emergency , the invest igator has the sole res ponsibilit y for determining if unblinding 
of a participant’s treatment assignment is warranted for medical management of the event.  The 
participant safety must always be the first consideration in making such a determinat ion.  If a 
participant’s treatment assignment is unblinded, Lilly must be notified immediately.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
promptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
6.4. Study Intervention Compliance
Study drug com pliance will  be determined by  the following:
Study drug administration data will be recorded by the patient in the patient study diary 
and reviewed by the investigator at each study visit.
The patients will be instr ucted to return any unused study drug and/or empt y cartons at 
the next visit to the study  site for the purpose of performing drug accountabilit y.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 36Treatment compliance for each visit interval is defined as taking at least 75% of the required 
doses of study  drug.  Similarly, a patient will be considered significant ly noncompliant if he or 
she is judged by  theinvestigator to have intent ionally or repeatedly  taken more or less than the 
prescribed amount of medication.
In addition to the assessment of a patient ’s compliance with the study drug administration, other
aspects of compliance wit h the study  treatments will be assessed at each visit based on the
patient’s adherence to the visit schedule, complet ion of study  diaries, and any other parameters 
the investigator considers necessary .  
Initially, patients considered to be poorly  compliant with their medicat ion and/or the study
procedures will receive addit ional training and instruction, as required, and will be reminded of
the importance of complying with the protocol.
6.5. Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter or prescript ion medicines and
acetaminophen/paracetamo l), vitamins, and/or herbal supplements that the participant is 
receiving at the time o f enrollment or receives durin g the study  must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
The Medical Monitor should be contacted if there are any  questions regarding conco mitant or 
prior therapy.
Initial doses of ti rzepatide delay gastric emptying and have the potential to transient ly impact the 
rate of absorption of concomitant ly administered oral medic inal products.  Ti rzepatide should be 
used with caution in patients receiving oral medi cinal products that require rapid gastrointestinal 
absorption following the init ial doses of t irzepatide as exposure to oral medications may be 
increased.
6.5.1. Hyperglycemia Rescue 
Although the use of rescue medications is allowable during the study , the use of rescue 
medications should be delayed, if possible, for at least 1 month after init iationof study drug. 
The date and time of rescue medication administration as well as the name and dosage regimen 
of the rescue m edication must be recorded.   
6.5.1.1. Hyperglycemia Rescue Criteria
Hyperglycemiarescue criteria will be determined from weekly fast ing self-monitored blood 
glucose (SMBG)values recorded in T2DM parti cipant diari es.  If anSMBG value equal or 
greater to the glycemic thresho ld for rescue (See definitions below) is recorded, that value should 
be confirmed by  repeat fast ing SMBG within 48 hours .  Intensification of T2DMtherapy should 
be initiatedif confirmed fasting glucose values are:
≥15.0 mmo l/L(270 mg/dL) from  baseline to Week 6 over at least a 2-week period (at 
least 2 consecutive values) post-randomizat ion
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 37≥13.3 mmo l/L(240 mg/dL) from Week 6 to Week 12 over at least a 2 -week period (at 
least 2 consecutive values)
≥11.1 mmo l/L(200 mg/dL) from  Week 12 to end of trial over at least a 2 -week period 
(at least 2 consecut ive values)
In addition, if HbA1c is > 9.0% at Week 12 or > 8.0% at Week 26 or later in the study, 
glucose-lowering therapy should be adjusted to improve glycemic control as outlined in 
Section6.5.1.2.  In the event a participant’s HbA1c values are less than these thresholds but are 
higher than what the investigator feels comfortable leaving untreated, glucose -lowering 
medication can be adjusted.   In addition, if patients develop symptoms of hyperglycemia (e.g. 
polyuria and po lydipsia), the invest igator should implement measures to determine glycemic 
control, and adjust as necessary .  For patients newly diagnosed with T2DM during the trial, 
SMBG and appropriate glucose -lowering therapy  should be initiated per protocol 
(Section6.5.1.2).
6.5.1.2. Hyperglycemia Rescue Medication
Participants with T2DMwho develop persistent severe hyperglycemia during the treatment 
period may be candidates for glucose-loweringrescue therapy and should be considered for 
addition of,or dose increase s of,glucose-lowering medicat ions.  
The study  site willsupplyrescue medication that will be obtained l ocally. Initiation or dose 
increase of the following may be used as rescue therapy :
Metformin
oDo not init iate or increase the dose of metformin when the eG FR 
<45mL/min/1.73 m2(or lower than country -specific thresho ld for using the 
prescribed dose of met formin per local label)
Sulfonylureas 
Long-acting basal insulin, when
oParticipant has persistent severe hyperglycemia, and
oParticipant is at maximal tol erated doses of m etformin and/or sulfonylurea (or has a n 
intolerance or contraindicat ion to these medicat ions)
Dose increasesof the following areNOT allowed during the study :  
SGLT-2 inhibitors
TZDs
Initiation of the following is NOT allowed during the study:
GLP-1 receptor agonists (See Section 5.2)
DPP-4 inhibitors ( See Section 5.2).  
SGLT-2 inhibitors
TZDs
While avo iding the classes of glucose-lowering medi cations not allowed by the protocol, 
investigators should fo llow national standards of care for diabetes management in respective 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 38participating countries or the American Diabetes Associat ion/European Associat ion for the Study  
of Diabetes gui dance (Inzucchi et al. 2015).
6.5.2. Management of Participants with Gastrointestinal Symptoms
In the Phase 2 program, t he most commo nly reported treatment -emergent adverse events 
(TEAEs) for participants receiving t irzepatide were nausea, vo miting, anddiarrhea.  To mit igate 
GI symptoms and manage part icipants with intolerable GI AEs, the invest igator should:  
Advise patients to eat smaller meals, for example, splitt ing 3 daily meals into 4 ,or 
moresmaller m eals, and to stop eating when they  feel full.  Also, patients may be 
informed that lower -fat meals could be better tol erated.
Prescribe symptomat ic medication (for example, ant i-emetic or antidiarrheal 
medication)per local country availabilit y and individual patient needs. Use of 
symptomaticmedication should be captured as concomitant medicat ion in the eCRF.
Temporarily interrupt study drug (omit 1 dose, the patient will take 3 of 4 doses at 
thatdose level). The data related to temporary  interruption of study treatment should 
bedocumented in source documents and entered on the eCRF.
After the interruption, restart at the same dose with the patient taking medicat ion to
alleviate their GI symptoms .
If intolerable GI symptoms or events persist despite the above measures, see Section 6.6.  
6.6. Dose Modification
Patients who do not tolerate the first dose escalat ion, in other words from 2.5 mg to 5 mg (or 
placebo equivalent), will need to discont inue from study treatment.  If a patient does not tolerate 
a dose level higher than 5 m g for 2 weeks (e.g., moderate -to-severe nausea, vo miting,or 
diarrhea)and the investigator does not believe that the patient will tolerate the dose with further 
exposure, then the invest igator may reduce the dose to the next lower 5 mg incremental dose
(e.g., 5 mg or 10 mg) .  If this dose is tolerated after 4 weeks, the dos e should be increased by 
2.5mg every 4 weeks unt il the target dose is achieved.  If this dose escalat ion is not tolerated, the 
dose should be reduced to the next lower 5 mg incremental dose that was tolerated (e.g., 5mg or 
10 mg).  The patient will remai n at that dose l evel for the durati on of the study .  Maintenance 
doses of 2.5 mg, 7.5 mg, or 12.5 mg will not be allowed.  
In order to m aintain blinding of the invest igator and patient, the investigator should call the 
IWRS to explain that the patient nee ds the dose reduced and IWRS will provide dispensing 
information.  Dose reductions may  occur at unschedul ed visits.
6.7. Intervention after the End of the Study
Tirzepatide will not be made available to participants after conclusion of the study .  
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 397. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
7.1. Discontinuation of Study Intervention 
Possible reasons leading to permanent discontinuatio n of invest igational product:
Subject Decisio n
othe participant or the participant’s designee(for example, parents or legal guardian)
requests to discont inue investigational product.
Investigator Decisio n
othe investigator decides that the patient should be discontinued fro m the study 
medication
Any medicat ion for weight loss is given for m ore than 1 week
Participantswill be discont inued from the investigational product in the fo llowing 
circumstances :
oDiagnosis of cirrhosis after randomizat ion (refer to Secti on 8.3.7.1for details)
oPancreatitis or pancreatic cancer (refer to Section 8.3.7.2for details) 
oDiagnosis of MTC after randomizat ion
oDiagnosis of an active or untreated malignancy  (other than basal  or squam ous 
cell skin cancer, in situ carcino mas of the cervix, or in situ prostate cancer) after 
randomization  
oAny severe inject ion site reaction ,or 2 or more moderate injection site reactions 
occurring a week or more apart
oAny significant study drug-related hypersensit ivity reaction
oAny TEAE, SAE, or clinically significant laboratory  value for which the 
investigator believes that permanent study  drug discontinuat ion is the appropriate 
measure to be taken
oAny TEAE or SAE considered possibly  or probably  related to study  drug that i s 
severe or m edically significant but not immediately  life-threatening; or where 
hospitalization or prol ongation of hospitalization is indicated; or is disabling; or 
limits self -care activit ies of daily living
oAny TEAE or SAE regardless of attribution to study  drug that has l ife-
threatening consequences or urgent intervent ion is indicated
oA female part icipant beco mes pregnan t
oDiagnosis of T1DM or latent autoimmune diabetes in adults
If the patient develops any exclusion criteria during the course of the study , the 
investigator should call the sponsor to determine whether discont inuation of study  drug is 
necessary
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 40Significant non-compliance with the protocol
If study drug is permanently discont inued, the patient should r emain in the study  if possible. The 
patient may continue participation in the study, attend all visit s, and undergo most protocol 
procedures.  
Participantsdiscontinuing from the invest igational product prematurely  for any reason shoul d 
complete AEand other fo llow-up procedures per Section 1.3(Schedule of Activities), 
Section8.3(Adverse Events and Serious Adverse Events), and Section 8.2(Safety Assessments) 
of the protocol.   
7.1.1. Interruption of Study Intervention
After rando mization, the invest igator ma y interrupt study drug, for exam ple, due to an AE (e.g., 
nausea and vo miting), or a clinically significant laboratory value.  If study  drug interruptionis 
due to an AE, the event is to be fo llowed and documented.  Every  effort shoul d be made by the 
investigator to ma intain patients in the study  and to restart study  drug prom ptly after any  
interruption, as soon as i t is safe to do so (See Section 7.1.2for restarting study  drug).  The dates 
of study drug interruption and restart must be documented.  The data related to interruption of 
study treatment will be documented in source documents an d entered on the eCRF.   Patient 
noncompliance should not be recorded as interruptionof study drug on the eCRF.  
7.1.2. Restarting Study Drug after Interruption
If the number of consecut ive missed doses is ≤2, the treatment can be restarted at the same dose, 
if the drug was well -tolerated pri or to discontinuation.
If the number of consecut ive missed doses is ≥3, then the treatment should be restarted at 
5 mg irrespective of the dose the patient was receiving before the interruption and 
subsequent ly follow the originaldose escalat ion scheme (i.e., beginning at 5 mg with 
2.5mg dose increments every 4 weeks to reach the assigned dose level).See Section 6.6
for guidance on dose escalat ion/maintenance for patients who do not tolerate a dose level 
of tirzepatide.
The invest igator will use the IWRS to receive the appropriate study drug dispensing 
information to preserve blinding o f the study drug
7.1.3. Interruption/Discontinuation due to a Hepatic Event or Liver Test Abnormality
Participants who are interrupted/discontinued from investigational product due to a hepatic event 
or liver test abnormalit y shouldhave addit ional hepatic safety data collected via case report form 
(CRF).  
Interrupti on/discont inuation of the investigational product for abnormal liver tests should be 
considered by the investigator when a participant meets one of the fo llowing condi tions after 
consultation wit h the Lilly -designated m edical monitor.  These cri teria differ based on the 
baseline liver test findings and are summarized below (Regev et al. 2019) .  If study  drug is 
interrupted, i t can be restarted only  if another eti ology is identified and liver enzymes return to 
baseline.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 41For participants with baseline ALT <1.5 X ULN and normal baseline bilirubin:
ALT or AST >8X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or INR >1.5 
ALT or AST >5 X ULN with the appearance of fatigue, nausea, vo miting, right 
upper-quadrant pain or tenderness, fever, rash, and/or eosinophilia ( >5%)
ALP >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fat igue, nausea, vomiting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia ( >5%)
For participants with baseline ALT ≥1.5 X ULN and normal baseline bilirubin:
ALT >5X baseline or ≥500 U/L (whichever occurs first)
ALT >2X baseline or ≥300 U/L (whichever occurs first) and TBL >2X ULN
ALT >3 X baseline or ≥300 U/L (whichever occurs first) with the appearance of 
fatigue, nausea, vo miting, right upper- quadrant pain or tenderness, fever, rash, 
and/or eosinophilia ( >5%)
ALP>3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fat igue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia ( >5%)
7.2. Participant Discontinuation/ Withdrawal from the Study
Participantswill be discont inued in the fo llowing circum stances:
Enrollment in any other clinical study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
Participation in the study  needs to be stopped for medical, safet y, regulatory, 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practice (GCP)
Investigator decision
othe investigator decides that the participant should be discontinuedfrom 
the study
oif theparticipant, for any reason, requi res treatm ent with another 
therapeutic agent that has been demo nstrated to be effect ive for treatment 
of the study  indication, discont inuation from the study  occurs pri or to 
introduction of the new agent
Participantdecision
othe participant or the pati ent’s designee, (for example, parents or l egal 
guardian)requests to be withdrawn fro m the study
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 42Participants discontinuing from the study  prematurely for any  reason shoul d complete AEand 
other safet y follow-up per Section 1.3(Schedule of Act ivities), Section 8.3(Adverse Events and 
Serious Adverse Events), and Section 8.2(Safety Assessments) of this protocol .
7.2.1. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ifiesaparticipantwho did not meet enrollment criteria and 
was inadvertently enrolled, then the patient should be discont inued from study treatment.
7.3. Lost to Follow -Up
Aparticipantwill be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.  Site personnel are expected to 
make diligent attempts to contact participants who fail to return for a scheduled visit or were 
otherwise unable to be fo llowed up by the site.
Site personnel, or an independent third party , will attempt to collect the vital status of the 
participantwithin legal and ethical boundaries for all participantsrandomized, including those 
who did not get invest igational product.  Public sources may be searched for vital status 
information.  If vital status is determined, this will be documented and the participant will not be 
considered lost to fo llow-up.
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
Discontinuati on of specific sites or of the study  as a who le are handled as part of 
Section10.1.7.2.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 438. Study Assessments and Procedures
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed within 60 days of receipt of conf irmed test results. Certain samples may 
be retained for a longer period, if necessary, to c omply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
Study procedures and their timing are summarized in the SoA (Section 1.3). Protocolwaivers or 
exemptions are not allowed.
Immediatesafety concerns should be discussed wit h the sponsor immediately  uponoccurrence or 
awareness to determine if the participant should cont inue or discont inue study intervention.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential participants 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participants screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
Procedures conducted as part of the participant’s routine clinical management (e.g., ophthalmic 
exam)and obtained before signing of the ICF may be utilized for screening or baseline purposes 
provided the procedures m et the protocol-specified criteria and were performed within the time 
frame defined in the SoA .
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with the 
samples.
8.1. Efficacy Assessments
8.1.1. Primary Efficacy Assessment
The primary  efficacy measurement in this study  is NASH reso lution with no worsening of 
fibrosisbasedon liver histol ogy at Week 52 compared withbaseline.  
In alignment with U nited States(US) Food and Drug Administration (FDA) draft guidance 
(FDA2018) and the EMA reflection paper (EMA2018 ), NASH resolution will be defined as:
absence offatty liver disease or simple steatosis without steatohepatit is; 
the absence of hepatocellular ballooning (NAS 0 for ballooning) 
with or without mild lo bular inflammat ion (NAS 0 or 1 for inflammat ion),and 
any value for steatosis.
No worsening of fibrosis will be defined as no increase in fibrosis stage fro m baseline to
Week52.  
Liverhistology will be evaluated via liver biopsiescollected at baseline in participants for who m 
a liver biopsy of adequate qualit y performed within 6months of screening is unavailable, and at 
Week 52 (end- of-treatment) in all  participantswho remained on study  drug.  Patients who 
discontinued study  drug prior to Week 36 will not have a second liver biopsy.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 44Histology will be scored according to the NASH CRN guidelines (Kleiner et al. 2005 ;Puri and 
Sanyal 2012).   Pathologists reviewing the liver biopsieswill be blinded to treatment group. 
Intra-and inter-observer variabilit y in assessment of histology will be assessed.   The glass slides 
may be scanned to facilitate future addit ional exploratory  analyses of the whole slide images.
Liver biopsy tissue block and slides will be retained at a facilit y selected by  Lilly or i ts designee 
for a maximum of 15 years after the last participant visit for the study , or for a shorter period if 
local regulati ons and ERBs impose shorter time limits.  This retent ion period enables use o f new 
technologies, response to regulatory  questions, and invest igation of variable response that m ay 
not be observed unt il later in the development of tirzepatide or after tirzepat ide becomes 
commercially  available.
8.1.1.1. Baseline Liver Biopsy
The baseline liver biopsy used for assessment may be a biopsy performed in the line of standar d 
care or be a new biopsy performed as part of screening, as described below .  
A prior liver biopsy  may be used for screening and assessment purposes when the biopsy 
was taken within 6months of screening, 
is available for review, and
is of adequate qualit y.  
In the case that a liver biopsy was performed previously, the invest igator should confirm if the 
tissue block and/or addit ional slides can be obtained.  The liver biopsy will then be analyzed by 
2central patho logists to confirm t hat the biopsy  is of adequate qualit y and there is histological 
evidence of NASH and fibrosis stage as defined in inclusion criterion 5(Section 5.1).  Clinical 
staff shoul d note that the date of the historical liver biopsy  establishes a hard window for 
completion of screening:  screening must take place within 6months of the date of the liver 
biopsy.  If the liver biopsy  is more than 6months old when t he participant enters screening, a 
new baseline liver biopsy  is required.  
Whenan acceptable liver biopsy is unavailable, one must be obtained for analyses by the 
2central patho logists.  A screening liver biopsy must only be co llected after patients hav e 
completed all screening assessments designated at Visit 1, met inclusion/exclusio n criteria, and 
thus, have a high likelihood of having NASH.  For participants using aspirin and/or NSAIDs, it 
is left to the discret ion of the investigator whether or not t o temporarily discont inue these 
medications prior to the liver biopsy procedure.  
8.1.1.2. Liver Biopsy Method
The qualit y of the histologic data obtained by liver biopsy is affected by several factors including 
the manner of procurement, the ty pe of biopsy, biopsy location, dimensio ns of the biopsy core 
and the inherent variabilit y in the subject ive assessment of liver histology (Sanyal et al . 2011).  
For this trial, the recommended method is a percutaneous biopsy  obtained from  the right lobe of 
the liver, if possible, and wit h at least a 16-gauge instrument.  Other biopsy methods , including 
transvenous (e.g., transjugular) methods or more than one sample obtained with a narrower bore 
(e.g.,18 gauge) instrument , may be used based on specific clinical considerations(e.g.,morbid 
obesity) or local expertise (Rockey et al. 2009).  The method emplo yed for liver biopsy should
be recorded in source documents and entered on the eCRF .  Whichever method is emplo yed, the 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 45liver biopsy t issue should be of adequate size ( 20mm or more in length is preferred ). Two 
central pathologists will assess the qualit y of the biopsy .  Specimens that are inadequate for 
evaluation of histology  will not be acceptable for inclusion of patients in the trial.
8.1.1.3. End-of-Treatment Biopsy
The biopsy should be obtained as described above for the baseline liver biopsy at the time 
specified in the SoA .  Ideally, the same procedure that was used for the baseline liver biopsy 
should be employed, so that a change in procedure is not a reason for changes in histological
features.  Similarly , the end-of-treatment biopsy shoul d be obtained fro m the same lobe of the 
liver as the initial biopsywhenever possible .  In the event a participant either discontinuesstudy 
drug or terminates early  fromthe study, end-of-treatment liver bi opsies may be perform ed ifthe:
participant has been on treatm ent for at least 36 weeks, and 
the liver biopsy should beperformed within 2 weeks oftreatment discont inuation.
8.1.1.4. Risk Mitigation for Liver Biopsies
The risk of bleeding is greatest init ially after liver bi opsy; thus, i t is recommended that patients 
areobserved carefully over the first several hours after biopsy.  Consensus guidelines for 
mitigating the risk of liver biopsies have been published (Rockey et al 2009).  This guidance 
states that v ital signs shouldbe frequently monitored (at least every  15 minutes for the first hour) 
after liver biopsy .  The minimum  recommended observat ion time after biopsy is between 2 to 4 
hours but may vary depending on l ocal expertise and practice.  Platelet count and INR shouldbe 
measured pri or to liver biopsy , as noted in the SOA .  The decision to perform liver biopsy in the 
setting of abnormal laboratory  parameters of hemo stasis should be reached as the result of local 
practices.
8.1.2. Secondary Efficacy Assessments
8.1.2.1. Histology Determined from Liver Biopsy
NAS
Fibrosis stage
8.1.2.2. Liver Fat Content Determined from Magnetic Resonance Imaging
As part of the magnetic resonance imaging ( MRI)evaluation, liver fat con tent will be determined 
using MRI –Proton Densit y Fat Fraction (MRI -PDFF).  The fat fract ion is the proportion of 
mobile protons in liver tissue attributable to fat, and is a noninvasive MRI -based bio marker of 
liver triglyceride concentrati on. 
Participants will undergo 3liver-directedMRI evaluations as outlined in the SoA (Section 1.3).  
MRI images will be transmitted to a central reader for evaluat ionof the MRI-based efficacy  
endpoints.  For patient safet y, images should also be over -read locally to assure there are no 
underlying liver pathologies other than NASH. 
In the event of early  terminati on from the study drug or the study , 
the second MR Iexam may  be perform ed when 
othe participant has been on treatment for at least 16 weeks , and
owithin 2 weeks of treatment discont inuation
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 46the third MR Iexam may be performed
owhen the participant has been on treatment for at least 36 weeks, and
owithin 2 weeks of treatment discont inuation
MRIs will be performed after a fast of at least 6 hours.  Participants are allowed to take necessary 
medications and small quant ities of water during the fast.  Addit ional exclusio n criteria apply for 
MRI examinat ion eligibilit y, which do not count toward eligibilit y for study participation.  These 
exclusions are:  
a contraindicat ion to MRI examinat ions
extreme claustrophobi a
weight or girth exceeds the scanner capabilit ies
any condit ion or circumstance that ,in the opinio n of the invest igator,would interfere 
with completion of MRI examinat ions
For patients with claustrophobia in MRI machines, investigators may o ffer, at their discret ion, a 
light sedative. However, if the patient is not willing to attempt MRI with light sedation, the 
patient should be excluded fro m the MRIevaluationbut should not be excluded fro m the study.
8.1.2.3. Body Weight
Patients will be weighed on an electronic scale in light clothing at approximately  the same time 
after an overnight fast (or fast of at least 8 hours) and evacuat ion of any bowel and bladder 
contents. SeeAppendix5(Section10.5).  The scale’s performance will be mo nitored at least 
monthly using standard wei ghts, and records of these assessments will be kept in the study  
binder.
8.1.3. Exploratory Efficacy Assessments
8.1.3.1. Histology Determined from Liver Biopsy
Additional histological measures will be scored by the pathologists.  These will include 
Expanded ballooning score
Expanded portal inflammat ion score
Expanded fibrosis stage 1 scores
Mallory-Denk bod y score
Glycogenosis score
Scores for steatosis, hepatocellular ballooning, and lobular inflammat ion
NASH reso lution based on overall assessment by pathologists
8.1.3.2. Magnetic Resonance Imaging – Iron-Corrected T 1 Imaging
During the MRI exam described above (Section 8.1.2.2), iron-corrected T 1imaging of the liver 
will be performed to measure hepat ic extracellular fluid content, which has been shown to 
correlate with hepatic inflammat ion and fibrosis (Pa vlides et al. 2017).  MRI images will be 
transmitted to a central reader for evaluation.
CONFIDENTIAL Protocol I8F-MC-GPHR(d) 
LY3298176 47 8.1.3.3. Transient Elastography (TE) 
CAP and LSM will be measured by TE (FibroScan) by experienced operators and per 
manufacturer’s recommendations.  TE measurements will be performed after a fast of at least 
3 hours.  Participants are allowed to take necessary medications and small quantities of water 
during the fast.   
For screening purposes, TE may be considered unreliable if the LSM interquartile range (IQR) 
divided by median LSM is greater than 30% (Hsu et al. 2019) or if the CAP IQR is >30 dB/m 
(Caussy et al. 2018).  In the event that TE is unreliable, the alternate criteria for eligibility for 
liver biopsy may be used (See Section 5.1, inclusion criterion 5).  In addition, the alternate 
criteria for eligibility for liver biopsy may be used if the LSM is >7.1 but ≤7.6 kPa and/or the 
CAP is >283 but ≤288 dB/m.  
In the event of early termination from the study drug or the study,  
 the second TE exam may be performed when  
o the participant has been on treatment for at least 16 weeks, and 
o within 2 weeks of treatment discontinuation 
 the third TE exam may be performed  
o when the participant has been on treatment for at least 36 weeks, and  
o within 2 weeks of treatment discontinuation 
8.1.3.3.1. Screening FibroScan-AST (FAST) Score 
The FAST score is used to identify patients with NASH who have NAS ≥4, and fibrosis stage ≥2 
as part of the inclusion criteria to reduce the number of patients who have a non-qualifying liver 
biopsy.  The score is based on a calculation (below) that includes the FibroScan LSM, the CAP, 
and AST level.  A value of FAST ≤0.35 had a negative predictive value of 0.85 in the derivation 
cohort (n=350) and 0.94 in the pooled external validation cohorts (n=1026) (Newsome et al. 
2020).  For Study GPHR, the FAST score must be >0.35 for a patient with a valid FibroScan to 
be eligible for screening liver biopsy.  The FAST score will be provided by the central laboratory. 
FAST Score Calculation:   
FAST = 𝑒ିଵ.଺ହାଵ.଴଻×୪୬(୐ୗ୑)ାଶ.଺଺×ଵ଴షఴ×CAPయି଺ଷ.ଷ×ASTషభ
1+𝑒ିଵ.଺ହାଵ.଴଻×୪୬(୐ୗ୑)ାଶ.଺଺×ଵ଴షఴ×CAPయି଺ଷ.ଷ×ASTషభ. 
In this formula, “ е” denotes the exponential constant, also known as Euler’s number, and “ln” 
denotes the natural logarithm function. 
8.1.3.4. Biomarkers  
Biomarkers will be collected during the study according to the SoA (Section 1.3) and change 
from baseline will be analyzed. 
See Section 8.8 for more information on biomarkers. 
8.1.3.5. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) 
The effect of tirzepatide on insulin sensitivity will be evaluated based on the change from 
baseline in HOMA-IR. 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 488.1.3.6. Waist Circumference 
Waist circumference will be collected according to the S oA(Section 1.3).  Waist circumference 
should be measured at the midpo int between the lower margin of the least palpable rib and the 
top of the iliac crest.  The patient should stand with feet close together, arms at the side and body 
weight evenly  distributed, and should we ar little clothing. The patient should be relaxed, and the 
measurements should be taken at the end of a normal expirat ion.  The m easurement should be 
repeated.  If the difference between the 2 measurements exceeds 1 cm, the 2 measurements 
should be repeat ed.
8.1.3.7. Patient Reported Outcomes (PRO)
Patient Global Impression of Severity (PGIS)
The PGIS is designed to assess the patients’ overall perception o f disease condit ion.This is a 
single glo bal item that asks participants to rate the overall severit y of their NASH disease 
conditionin the past 7 day s on a 5-point scale ranging fro m “no symptoms” to “very  severe.”
Chronic Liver Disease Questionnaire for Nonalcoholic FattyLiver Disease (CLDQ -
NAFLD)
The Chronic Liver Disease Quest ionnaire –Nonalcoholic Fatty  Liver Disease (CLDQ- NAFLD) 
is a disease -specific instrument consist ing of 36 items that assess 6 domains: Abdominal 
Symptoms (3 items), Act ivity/Energy (5 items), Em otional Health (9 items), Fatigue (6 items), 
Systemic Symptoms (6 items), and Worry  (7 items) (Younossi  et al. 2017).  Item s are rated on a 
7-point scale ranging fro m “1 –All of the time” to “7 –None of the time.” Scores are calculated 
separately  for each domain by taking the average of the do main’s items. A total score is 
calculated by taking the average of the domain scores.  Higher scores reflect better health. The 
CLDQ-NAFLD was ori ginally developed with a recall period of “the last 2weeks,” but fo r this 
study, permissi on has been obtained fro m the developers to modify the recall period to “the last 
week.” The CLDQ -NAFLD has previously been validated in people wit h NASH wit h F3 and F4 
fibrosis (Younossi et al. 2019).
PROMIS Short Form Fatigue 8a v1.0
The Patient-Reported Outcome Measurement Informat ion System (PROMIS) i s a set of 
person-centered m easures that evaluates and mo nitors physical, mental, and social  health in 
adults and children (H ealthMeasures [WWW] ).  It can be used with the general populat ion and 
with individuals living with chronic condit ions.  The PROMIS Short Form  Fatigue 8a assesses 
self-reported symptoms fro m mild subject ive feelings o f tiredness to an overwhelming, 
debilitating, and sustained sense of exhaustion that likely decreases one’s abilit y to execute daily 
activities and funct ion normally. The PROMIS Short Form Fat igue 8a consists of 8items each 
rated on a 5 -point scale ranging from “1 -not at all” to “5 -very much.” Items have a recall 
period of “the past 7 day s.” Individual item scores are totaled to obtain a raw score, with higher 
scores indicating more interference. Raw scores can be converted to a T- score, which is 
standardized with a mean o f 50 and a standard deviat ion(SD)of 10.
PROMIS Sh ort Form Pain Interference 4a v1.0
The PROMIS Short Form Pain Interference 4a assesses consequences of pain on relevant aspects 
of one’s life.  This includes the extent to which pain hinders engagement with social, cognit ive, 
emotional, physical, and recreational act ivities.  The PROMIS Short Form Pain Interference 4a 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 49consists of 4items that asks participants to rate their pain interference over the past 7 days on a 
5-point scale ranging fro m “1 -not at all” to “5 -very much.”  Individua l item scores are total ed 
to obtain a raw score, with higher scores indicating more interference. Raw scores can be 
converted to a T -score, which is standardized wit h a mean of 50 and a nSDof 10.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provi ded in the SoA (Section 1.3).
8.2.1. Physical Examinations
A complete physical examinat ion will be performed at screening.  Additional physical 
examinations may be performed throughout the study  if determined necessary  due to parti cipant 
symptoms.
8.2.2. Vital Signs
Sitting BP,pulse rate, and body  temperaturewill be m easured according to Section1.3. Vital 
sign measurem ents shoul d be taken before obtaining an electrocardi ogram (ECG)tracing and 
before collection of blood samples for laboratory  testing, at vi sits where required ( See Section
1.3).  The participant should be required to sit quietly for 5minutes before vital sign 
measurements are taken.  An appropriately sized cuff (cuff bladder encircling at least 80% of 
the arm) should be used to ensure the accuracy  of BP measurements.  The arm used for the BP 
measurement should be supported at heart lev el. At Visit 1 (screening), to determine which arm 
should be used to collect BP and pulse rate throughout the study, BP and pulse rate will be 
measured once in each arm, and the arm that had the higher systolic BP should be used to 
collect both measuremen ts of both BP and pulse rate at all study visits.  For each parameter (PR, 
systolic BP, and diastolic BP), 2 measurements will be taken using the same arm; the recordings 
should be taken at l east 1 minute apart, and each measurement of sitting pulse rate and BP will 
be recorded in the eCRF ; temperature does not need to be recorded in the eCRF .  Any AE 
related to changes in BP and pulse rate should be reported.
8.2.3. Electrocardiograms
For each patient, 12 -lead ECGs should be co llected according to Section 1.3.Patients must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine, but awake, 
during ECG collect ion.
Electrocardiograms s hould be recorded in triplicateaccording to study -specific recommendat ions 
included in the Manual of Operat ions for the study, using standardized equipment provided by 
the sponsor.
Consecutive replicate ECGs will be obtained at approximately 1 -minute inte rvals.  
Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary .  
Collection of more ECGs than expected at a particular time point is allowed when needed to 
ensure high -quality records.
Electrocardiograms will init ially beinterpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally  
while the patient is st ill present, to determine whether the subject meets entry criteria and for 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 50immediate subject management, should any clinically  relevant findings be ident ified.  Any 
clinically significant findings fro m ECGs that result in a diagnosis and that occur after the patient 
receives the first dose of the invest igational treatment should b e reported to Lilly  or its designee 
as an AE.  The investigator (or qualified designee) is responsible for determining if any change 
in patient management is needed, and must document his/her review of the ECG printed at the 
time of evaluat ion.
After enro llment, if a clinically significant increase in the QT/QTc interval fro m baseline or 
other clinically significant quantitative or qualitat ive change fro m baseline is identified, the 
patient will be assessed by the invest igator for symptoms (e.g., palpitatio ns, near syncope, and 
syncope) and to determine whether the patient can continue in the study .  The invest igator or 
qualified designee is responsible for determining if any change in pat ient management i s needed 
and must document his/her review of the ECG printed at the time of evaluation fro m at least 1 of 
the replicate ECGs from each t ime point.
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electronically transmitted to a designated central ECG laboratory .  The centra l ECG laboratory  
will perform a basic qualit y control check (e.g., demographics and study  details) and then store 
the ECGs in a database.  At a future time, the stored ECG data may be over -read by a 
cardiologist at the central  ECG laboratory  for further evaluation of machine -read measurements 
or to meet regulatory requirements.
The machine-read ECG intervals and heart rate may  be used for data analysis and report -writing 
purposes, unless a cardio logist over-reading of the ECGs is conducted prior to complet ion of the 
final study  report (in which case, the over -read data would be used).
In addition, for each patient, a single ECG will be recorded at screening and if the patient 
discontinues from  the study  prematurely for immedi ate patient management. These EC Gs will 
be stored at the invest igation site.
Any treatment -emergent clinically significant ECG finding result ing in a diagnosis shoul d be 
reported as an AE in the eCRF.
8.2.4. Clinical Safety Laboratory Assessments
With the exception o flaboratory test resul ts that may  unblind the study , Lilly or i ts designee will 
provide the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor is used for the clinical trial.  
See Appendix 2 (Section10.2)for the list of clinical laboratory  tests to be performed and to the 
SoA (Section1.3) forthe timing and frequency.
The invest igator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study  in the AE section of the CRF. The 
laboratory  reports m ust be filed wit h the source documents. Clinically significant abnormal 
laboratory  findings are those which are not associated with the underlying disease, unless judged 
by the investigator to be more severe than expected for the p articipant's condit ion.
All laboratory  tests with values considered clinically  significantly abnorm al during parti cipation 
in the study  or within 1 monthafter the last dose of study  intervention should be repeated until 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 51the values return to normal or base line or are no longer considered clinically significant by  the 
investigator or medical mo nitor.
If such values do not return to normal/baseline wit hin a period of time judged reasonable by  the 
investigator, the etiology  should be identified and the sponsor notified.
All protocol -required laboratory  assessments, as defined in Appendix 2 (Section10.2), must be 
conducted in accordance with the laboratory  manual and the SoA.
If laboratory  values from nonprotocol specified laboratory  assessments perform ed at the 
institution’s local laboratory  require a change in parti cipant management or are considered 
clinically significant by  the investi gator (e.g., SAE orAE or dose modificat ion), then the resul ts 
must be recorded in the eCRF.
8.2.4.1. Immunogenicity Assessment 
Where local regulat ions and ERBs allow, blood samples for immunogenicit y testing will be 
collected to determine ant ibody production against tirzepatideas specified in the S oA
(Section1.3).
At the visits and times specified in the S oA(Section1.3), venous blood samples will be co llected 
to determine ant ibody production against tirzepatide.  To interpret the results of immunogenicit y, 
a PKsample will be collected at the sam e time po intsas the immunogenicit y samples in all post -
baseline samples to determine the plasma concentrations o f tirzepatide.  All sam ples for 
immunogenicit y should be collected predose when applicable and possible. 
Additional samples (including ADA, PK, and exploratory  immune safet y samples) maybe 
collected if there is a possibilit y that an AE is immuno logically mediated (See Section8.3.7.10)
“Hypersensit ivity Events”).  Instructions for the collect ion and handling of blood samples will be 
provided by the sponsor.  The actual date and time (24 -hour clock time) of each sampling will be 
recorded.   Sample co llected at Visit 801 will assess immunogenicit y at washout of tirzepatide 
(5half-lives post end of treatment).
Treatment -emergent ADAare defined in Section9.4.6.  
A risk-based approach will be used to monitor patients who develop treatment-emergentADA 
after treatm ent with tirzepatide. Clinically significant treatment-emergentADA will be defined 
as any treatment-emergent ADA at the fo llow-up visit (Visit 801) with:
A high (≥1:1280) or increasing titer at the follow-up visit (V801)
An associ ation of treatment-emergent ADA with a moderate -to-severe inject ion site 
reaction or infusi on-related reacti on
Patients who are treatment-emergent-ADA posit ive at the last scheduled assessment or 
discontinuat ion visit will have addit ional samples taken at 3, 6, 9 (optional), and 12 months 
postlast assessment unt il the titer returns to within 2 -fold of baseline t iter or for up to 1 year, 
whichever i s less.  Patients fo llowed for at least 1 year since last dose whohave not returned to 
baseline as defined above will be assessed for safety concerns.  If no clinical sequelae is 
recognized by the clinical  team, then no further follow -up will be required.
Immunogenicity will be assessed by  a validated assay  designed to detect and titerADAin the 
presence of tirzepatideat a laboratory  approved by the sponsor .  Samples with detected ADA 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 52will be tested for cross -reactivity binding to native GIP and GLP -1. Antidrug antibodi es may be 
further evaluated for their ability to neutralize the activit y of assigned treatm ent (tirzepatide 
neutralizing ant ibodies).  Antidrug antibody samples wi th detected cross-reactive binding to 
native GIP and /orGLP-1may be further evaluated for neutralizing ant ibodies against nat ive GIP 
and/orGLP-1, respectively.    
Samples will be retained for a m aximum of 15 years after the last participant visit, or for a 
shorter period if local regulat ions and ERBs allow, at a facilit y selected by the sponsor.  The 
duration allows the sponsor to respond to future regulatory  requests related to the tirzepatide.  
Any samples remaining after 15 y ears will be destroyed. 
8.2.4.2. Hepatic Safety Monitoring
Participants with NASH may  have normal  or elevated ALT and fluctuations of ALT are part of 
the natural course of the disease.  Therefore, assessment of possible drug -induced liver injury 
(DILI) must take into account the baseline ALT (Regev et al. 2019).   Possible DILI will be 
adjudicated by  a committee ofphysicians external to Lilly  with hepatic expertise.  This 
committee will be blinded to study  assignment.   Additional clinical and laboratory  monitoring 
(Appendix 3 Section10.3) is required if a parti cipant experiences any  of the following elevations 
of liver tests while in the study .
For participants with baseline ALT <1.5 X ULN and normal baseline bilirubin:
Elevation of ALT ≥5X ULN
Elevation of ALT ≥3 XULN and presence of severe fat igue, nausea, vo miting, 
right upper quadrant pain
Elevation of ALP ≥2X ULN
Elevation of TBL ≥2 XULN
For participants with baseline ALT ≥1.5 X ULN and normal baseline bilirubin:
Elevation of ALT ≥3 X baseline or ≥300 U/L (whichever occurs first)
Elevation of ALT ≥2 X baseline or ≥ 300 U/L (whichever occurs first) and 
presence of severe fat igue, nausea, vo miting, right upper quadrant pain
Elevation of ALP ≥2X ULN
Elevation of TBL ≥2 XULN
Baseline ALT is derived fro m anaverage of 2pretreatm ent ALT m easurements at l east 2 weeks 
apart. Elevated baseline is defined as ALT ≥ 1.5XULN. In participantswith a sizable stable 
decrease in ALT ( >50% of the baseline value) during treatment, a new baseline, corresponding to 
the ALT nadir, should be established on an individual basis for subsequent determinat ion of a 
possible DILI signal.
For participants with Gilbert’s syndrome, the criterio n of elevat ion of TBL ≥2X ULN shoul d be 
replaced by a doubling of di rect bilirubin or incr eased INR to >1.5.
If a study participantmeets any o f the above criteria during the study , liver testing (Section 10.3) 
should be repeated wi thin 48 to 72 hours including ALT, AST, ALP, TBL, direct bilirubin, 
gamma-glutamyl transferase, and creatine kinase to confirm the abnormalit y and to determine if 
it is increasing or decreasing.  If the abnormalit y persists or worsens, clinical and laboratory  
monitoring shoul d be initiated by the invest igator and in consultation wit h the study  medical 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 53monitor.  Monitoring of ALT, AST, TBL, and ALP should continue unt il levels normalize or 
return to approximate baseline levels. 
Additional safety data should be co llected via eCRFif 1 or more of the following condit ions 
occur: 
participant meets any of the above criteria that trigger addit ional hepatic safety 
monitoring on 2 or more consecut ive blood tests
participant discont inued from treatment due to a hepatic event or abnormalit y of 
liver tests
hepatic event considered to be a nSAE
8.3. Adverse Events and Serious Adverse Events
Investigators are responsible for monitoring the s afety ofparticipants who have entered this 
study and for alerting Lilly  or its designee to any  event that seem s unusual, even if this event 
may be considered an unant icipated benefit to the participant.
The invest igator is responsible for the appropriate medical care of participantsduring the study .
Investigators must document their review of each laboratory  safety report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medic ally important, considered rel ated to the invest igational 
product or the study , or that caused the participantto discont inue the invest igational product 
before complet ing the study.  The participant should be fo llowed until the event resolves, 
stabilizes with appropriate diagnostic evaluat ion, or is otherwise explained.  The frequency  of 
follow-up evaluat ions of the AE is left to the discretion of the investigator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRFthe occurrence and nature of 
eachparticipant’s preexist ing condit ions, including clinically  significant si gns and symptom s of 
the disease under trea tment in the study .  In addition, site personnel will record any  change in the 
condition(s) and any  new condi tions as AEs. Investigators shoul d record thei r assessment of the 
potential relatedness of each AE to protocol procedure or investigational produc t via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatment, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device,and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgica l interventions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If aparticipant’s investigational product is discont inued as a result of an AE, study  site personnel  
must report this to Lil ly or its designee via eCRF, clarifying if possible, the circumstances 
leading to any  dosage m odifications, or di scontinuati ons of treatment.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 54Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacity
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or resul t in 
death or hospitalizat ion but may jeopardize the participantor may require 
intervention to prevent one of the other outcomes listed in the definit ion above.  
Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home, blood dyscrasias or 
convulsio ns that do not result in inpatient hospitalization, or the development of 
drug dependency  or drug abuse.
All AEs occurring after signing the ICF are recorded in the eCRFand assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the participant has signed the ICF and has 
received invest igational product.  However, if an SAE occurs after signing the ICF, but prior to 
receiving invest igational product , the SAE should be reported to the sponsor as per SAE 
reporting requirements and t imelines ( See Section8.3.1)if it is considered reasonably  possibly 
related to study  procedure.
Study site personnel  must alert Lilly or i ts designee of any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed with official notification on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow-up SAE 
information.Participants with a serious hepatic AEshould have addit ional data collected using 
the eCRF.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definition of an AE.  However, to fulfill regulatory re quirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (theparticipant disposition CRF has been com pleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly related to the 
study treatment or study  participation, the invest igator must promptly notify Lilly .
Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigat or identifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory  requirements in parti cipating countries 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 55require the reporting of SUSARs.  Lilly has procedures that will be followed for the 
identification,recording ,and expedited reporting of SUSARs that are consistent with global 
regulations and the associated detailed guidances.
8.3.1. Time Period and Frequency for Co llecting AE and SAE Information
All SAEs and AEs will be collected from the signing of the ICFthroughthe follow-up visitat the 
time points specifi ed in the SoA (Secti on1.3).
Medical occurrences that begin before the start of study  intervention but after obtaining informed 
consent will be recorded on the Medical History /Current Medical Condit ions section of the CR F 
not the AE sect ion.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours. The investigator will submit any updated SAE data to 
the sponsor within 24 hours of i t being available.
Investigators are not obligated to actively seek AE or SAE after conclusio n of the study  
participation.However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervention or study  participation, the invest igator must prompt ly notify the 
sponsor.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading ver bal questioning of the participant is the preferred method to inquire about 
AEoccurrences .
8.3.2. Follow-Up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs, and nonseri ous AEs of special interest (as defined in 
Section 8.3.7), will be fo llowed until resolution, stabilizat ion, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Secti on1.3). 
8.3.3. Regulatory Reporting Requirements for SAEs
Prompt notificat ion by the invest igator to the sponsor of a nSAE is essent ial so that 
legal obligations and ethical responsibilit ies towards the safet y of participants and the 
safety of a study intervention under clinical invest igation are met.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory authority and 
other regulatory  agencies about the safet y of a study intervention under clinical 
investigat ion. The sponsor will co mply with country-specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority, Institutional Review Boards 
(IRB)/Independent Ethics Co mmittees (IEC) , and investigators.
Investigator safet y reports must be prepared for SUSARsaccording to local regulatory  
requirements and sponsor policy and forwarded to investigators as necessary .
An investigatorwho receives an invest igator safety report describing a nSAE or other 
specific safet y information (e.g., summary or list ing of SAEs) fro m the sponsor will 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 56review and then file it along wit h the IBand will notify the IRB/IEC, if appropriate ,
according to local requirements.
8.3.4. Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of 
male participants will be collected after the start of study  intervention and until 1 month 
after the last dose of study  drug for female participants and 3 months after the last dose 
of study drugfor male participants.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should fo llow the procedures outlined in Appendix 8 
(Section10.8).
Abnormal pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
8.3.5. Medical Device Incidents (Including Malfunctio ns)
Medical devices (prefilled sy ringes) are being provided for use in this study  for administration of 
the study drug. In order to fulfill regulatory  reporting obligat ions worldwide, the invest igator is 
responsible for the detection and documentation of events meet ing the definitions of incident or 
malfunction that occur during the study  with such devices.
The definit ion and directions for reporting of a Medical Device Incident can be found in 
Appendix 7 Section 10.7).
NOTE: Incidents fulfilling the definit ion of an AE/SAE will also fo llow the processes outlined 
in Section8.3.2. 
The invest igator will pro mptly report all incidents occurring with any medical device 
provided for use in the study  in order for the sponsor to fulfill the legal responsibilit y to 
notify appropriate regulatory  authorities and other ent ities about certain safet y 
information relating to medical devices being used in clinical studies.
The invest igator, or responsible person according to local requirements (e .g., the head 
of the medical inst itution), will comply with the applicable local regulatory  
requirements rel ating to the reporting of incidents to the IRB/IEC.
8.3.6. Complaint Handling
Lilly collects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, m onitor quality, and to 
facilitate process and product improvements.
Participants will be instructed to contact the invest igator as soon as possible if he or she has a 
complaint or probl em with the invest igational product or drug delivery system so that the 
situation can be assessed.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 578.3.7. Adverse Events of Special Interest
The following are adverse events of special interest (AESI) and will be adjudicated by an 
external adjudicat ion committee :  
NASH-related clinical events
Pancreatitis
Major adverse cardio vascular events
Deaths
The following are addi tional AESI for this program that will not be adjudicatedby an external
committee :  
Hepatobiliary  disorders
Hypoglycemia 
Thyroid malignancies and C -cell hyperplasia 
Supraventricular arrhythmias and cardiac conductive disorders
Diabetic retinopathy co mplications
Allergic/h ypersensit ivity reactions.  Includes injectio n site reactions and ADAformation.
Severe GI AEs
Acute renal events
Sites should collect addi tional details and data regarding AESIs, as instructed on the applicable 
eCRFs, and detailed below.
8.3.7.1. NASH-Related Clinical Events
All TEAEsof cirrhosis, ascites (clinically  evident), esophageal variceal hemorrhage, hepat ic 
encephalopathy , subacute liver failure (including liver transplantation), hepatocellular carcinoma, 
increase in Model for EndStage Liver Disease (MELD) score>15 or liver -related mortality 
should be evaluated and addit ional diagnostic tests performed, as needed.  These events will be 
adjudicated by  an external adjudication committee.   
Study drug shoul d be discont inued for any pat ient who develops a clinical diagnosis of ci rrhosis 
(e.g., evidence o f hepatic decompensation, etc.) after randomizat ion.  For purposes of safet y 
evaluation, patients with treatment-emergent cirrhosis may be followed in the study  until study  
end, unless the invest igator decides that the participant should be discontinued from the study.
8.3.7.2. Pancreatitis
Acute pancreat itis is defined as an AE of interest in all trials with t irzepatide, includ ing this trial.  
Acute pancreat itis is an acute inflammatory  process of the pancreas that may  also involve 
peripancreatic tissues and/or remote organ sy stems (Banks and Freeman 2006).  The diagnosis of 
acute pancreatit is requires 2 of the fo llowing 3 featu res: 
Abdominal pain, characterist ic of acute pancreat itis (generally located in the epigastrium 
and radiates to the back in approximately  half the cases) (Banks and Freeman 2006; 
Koizumi et al. 2006); the pain is often associated with nausea and vomit ing
Serum amylase (total and/or pancreat ic) and/or lipase ≥3X ULN
Characteristic findings of acute pancreat itis on computed tomography (CT) scan or MRI.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 58If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase a nd lipase) should be obtained via the central laboratory  (and locally, if needed). 
Imaging studies, such as abdo minal CT scan with or without con trast, MRI, or gallbladder 
ultrasound, should be performed.  If laboratory  values and/or abdominal imaging sup port the 
diagnosis of acute pancreat itis, the patient must discontinue therapy wit h tirzepatidebut will 
continue in the study .  A review of the patient’s conco mitant medications should be conducted to 
assess any  potential causal relationship wi th pancreatit is.
Each AE of pancreat itis must be reported. If typical signs and/or symptoms of pancreatit is are 
present and confirmed by laboratory  values (lipase or amylase [total and/or pancreatic]) and 
imaging studies, the event must be reported as an SAE .  For a potenti al case that does not meet 
all of these criteria, it is up to the invest igator to determine the seriousness o f the case (AE or 
SAE) and the relatedness of the event to study  drug(s).
Each patient will have measurements of p -amylase and lipa se (assessed at the central laboratory ) 
as shown in Sect ion1.3(SoA) to assess the effects of the invest igational doses of t irzepatideon 
pancreatic enzyme levels.  Serial measures of pancreatic enzymes have limited clinical value for 
predicting episodes of acute pancreatit is in asymptom atic patients (Nauck 2016; Steinberg et al. 
2017a; Steinberg et al. 2017b).  Thus, further diagnostic fo llow-up of cases of asymptomat ic 
pancreatic hyperenzymemia (lipase and/or pancreatic amylase ≥3X ULN) is not mandated but 
may be performed based on the invest igator’s clinical judgment and assessment of the patient’s 
overall clinical condit ion.  Only cases of pancreat ic hyperenzymemia that undergo addit ional 
diagnostic follow-up and/or are accompanied by  symptom s suggestive of pancreatit is will be 
submitted for adjudicat ion.
All suspected cases of acute or chronic pancreat itis will be adjudicated by  an independent 
clinical endpoint committee.  In addit ion, AEs of severe or serious abdo minal pain o f unknown 
etiology will also be submitted to the adjudicat ion committee to assess for possible pancreat itis 
or other pancreat ic disease.  Relevant data from patients with acute or chronic pancreat itis and 
those with severe or seri ous abdominal pain will be entered into a specifically designed eCRF 
page by study site.  The adj udication commi ttee representative will enter the results of 
adjudication in a corresponding eCRF page.
8.3.7.3. Major Adverse Cardiovascular Events
Nonfatal cardiovascular ( CV)AEs will be adjudicated by  a committee of physicians external to 
Lilly with cardiology expertise.  Thi s committee will be blinded to treatment assignment.  
The nonfatal CV AEs to be adjudicated include : 
MI
hospitalization for unstable angina
hospitalization for heart failure
coronary interventions, such as coronary  artery bypass graft or perc utaneous coronary  
intervention
cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 598.3.7.4. Deaths
All deaths will be adjudicated by  a committee of physicians external to Lilly .  This committee 
will be blinded to treatment assignment.
8.3.7.5. Hepatobiliary Disorders
All events of TE biliary  colic, chol ecystitis, orother suspected events related to gallbladder 
disease shoul d be evaluated and addit ional diagnostic tests performed, as needed.  In cases of 
elevated liver enzymes, hepatic monitoring shoul d be initiated as outlined in Sect ions8.2.4.2
and10.3.
8.3.7.6. Hypoglycemia
Upon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia 
and how to treat it. Additionally, at Visit 3 participants with T2DM will receive glucom eters to 
monitor glycemia and will be trained on how to collect appropriat e information for each episode 
of hypoglycemia in the study .
When diagnosing and categorizing an episode considered to be related to hy poglycemia, 
investigators should use definit ions and criteria in accordance with the 2017 American Diabetes 
Association position statem ent on glycemic targets (ADA 2017), as described in Appendix 4
(Section 10.4).
Management of Hypoglycemia
Participants who devel op persistent or recurrent hypoglycemic episodes (clinical symptoms of
hypoglycemia and/or blood glucose [BG]-confirmed symptomat ic BG hypoglycemia [BG
concentration ≤3.0mmol/L (54mg/dL)]) during the treatment period will be asked to reduce the
dose or disc ontinue any conco mitant glucose-lowering medicat ions.
The occurrence of hypoglycemia wit h GLP-1 receptor agonists has been reported to be
higher in pat ients receiving concomitant sulfo nylurea therapy  (Trujillo et al. 2015).For
patients treated with a s ulfonylurea, the occurrence of (a) hypoglycemic episode(s)
should prompt consideration by the invest igator of a dose reduction or discont inuation of
the sulfonylurea.
For participants who are not on a sulfonylurea but are on dual oral treatment of
metformin and SGLT -2 inhibitors, in case o f (a) hypoglycemic episode(s), the dose of
metformin should be reduced or discont inued prior to reducing/discont inuing SGLT -2
inhibitors. The rationale for discont inuing met formin prior to SGLT -2 inhibitors is that
the latter may have an effect on liver fat content (Ohki et al. 2016).
When hypoglycemia develops in pat ients on any oral monotherapi es, the dose of this oral
medication should be reduced or di scontinued.
Hypoglycemic episodes will be recorded on a specific eCRF.  Informat ion regarding severit y, 
time of day , and invest igator’s opinio n of relatedness to study drug and procedure will be 
recorded. Hypoglycemia episodes should not be recorded as AEs unless the event meets serious 
criteria. 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 60Avoidance of Hypoglycemia
Temporary discontinuation of conco mitant antihyperglycemic medicat ions <14 consecut ive days
is allowed for certain clinical situat ions in order to avo id hypoglycemia (for example, severe
dehydration, elective surgery, or need for radio logic examination involving intravenous iodinated 
contrastdye).
Tirzepatide hasglucose-lowering efficacy  (Frias et al. 2018). Thus,it is possible that some
participants m ay achieve normal glycemia (e.g., HbA1c <5.7%) during the study . To avoid the
potential for future hypoglycemia as the patient cont inues in the study , investigators may,at their
discretion, choose to di scontinue glucose -lowering medicat ionother than study  drug.
8.3.7.7. Thyroid Malignancies and C -Cell Hyperplasia
Individuals with personal or family history of MTC and/or multiple endocrine neoplasia t ype 2 
(MEN-2)will be excluded fro m the study.  
The assessment of thy roid safety during the tri al will include reporting of any  case of thyroid 
malignancy including MTC and papillary carcino ma and measur ements of calcitonin.  This data 
will be captured in specific eCRFs.  The purpose of calcitonin measurements is to assess the 
potential of tirzepatide to affect thy roid C-cell function, which may  indicate development of 
C-cell hyperplasia and neoplasms.
Study drug should be discont inued (after first confirming the value) if postrandomizat ion serum 
calcitonin value increases.  
For eGFR ≥60 mL/min:  ≥20 pg/mL and has increased ≥50% over the screening value.  
For eGFR <60 mL/min:  ≥35 pg/mL and has increased ≥50% over baseline.  
A consultat ion with a thyroid specialist (if not available, an endocrino logist) should be obtained.  
If the increased calcitonin value is observed in a patient who has administered a medicat ion that 
is known to increase serum calcito nin, this medicatio n should be stopped and calcitonin levels 
should be measured after an appropriate washout period.  If the confirmed calcitonin value is <20 
pg/mL (eGFR ≥60 mL/min) or < 35 pg/mL(eGFR <60 mL/min), tirzepatide should be restarted 
oncesafe to do so.  
8.3.7.8. Supraventricular Arrhythmias and Cardiac Conduction D isorders
Treatment -emergent cardiac conduction disorders will be further evaluated. Patients who 
develop any event from these groups of disorders should undergo an ECG which should be 
submitted to the central reading center.  Addit ional diagnostic tests to determine exact diagnosis 
should be perform ed, as needed.  The specific diagnosis will be recorded as an AE.  Events that 
meet criteria for serious conditions must be reported as SAEs .
8.3.7.9. Diabetic Retinopathy Complications
Patients with T2DM who have a history  of proliferative diabet ic retinopathy, diabet ic 
maculopathy ,or severe nonproliferative diabet ic retinopathy  that requi res acute treatment will be 
excluded fro m the protocol  due to the potential risk of early  worsening of ret inopathy with the 
significant gl ucose lowering that is possible with t irzepatide.  
For patients with T2DM, the results of a dilated retinal fundoscopic exam performed by  an eye 
care professio nal (ophthalmo logistor optometrist) within 12 m onths prior to randomization will 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 61be recorded onthe preexist ing condit ions and medical history  eCRF as a baseline measure of 
retinopathy .  A follow-up, dilated fundoscopic exam should be performed when clinically 
indicated by  any AEsuspected of worsening retinopathy , and the findings should be recorded as 
an AE.
8.3.7.10. Hypersensitivity E vents
All allergic or hy persensitivity reactions will be reported by the invest igator as either AEs or, if 
any serious criterion is met, as SAEs.  Add itional data, such as type of reaction and treatment 
received, will be collected on any AEs or SAEs that the investigator deems related to study drug 
via the eCRF created for this purpose.  Study  drug shoul d be temporarily  interrupted in any  
individual sus pected of having a severe or serious allergic reaction to study  drug.  Study  drug 
may be restarted if and when it is safe to do so, in the opinion o f the investigator.  If study drug is 
permanently discont inued, the patient should cont inue in the trial to collect all planned efficacy 
and safety measurements.
Lab testing should be performed at the time of a systemic hypersensit ivity event. The 
management of the AEmay warrant lab oratorytesting beyo nd that described below and should 
be perform ed as clinically  indicated.
In the presence of generalized urticaria orif anaphyla xis is suspected and after the subject has 
been stabilized, samples described below should be obtained within 1 -2 hours of the event; 
however, samples may  be obtained as late as 12 hours after the event as analy tes can rem ain 
altered for an extended period of time . The time at which the sample was collected should be 
recorded and a follow-up sample should be obtained at the next regularly scheduled visit or after 
4 weeks, whichever is later.
Analytes to be evaluated in the sample:
Tryptase
ADAand tirzepatideconcentrati on (PK)
oIf a drug specific immunoglobulin E ( IgE)assay is notavailable, a commercially 
available alternat ive test that can indicate the presence o f drug-specific IgE in serum is 
the basophil act ivation test (BAT)
Complement
oC3a and C5a
Cytokines
oIL-6, IL-1β, IL-10 (or any cytokine panel that includes these 3 cytoki nes)
8.3.7.11. Injection Site Reactions
All injection site reactions and information regarding their time o f day, time relative to 
injection, size, amount of ery thema, indurat ion, and pruritus, as well as severit y, will be 
recorded on specific CRFs.  In addit ion, ifthe reaction is clinically significant, the site should 
attempt to contact the sponsor for potential fo llow-up procedures.  Inject ion site reactions do not 
need to be recorded as AEs as well unless they  meet SAE cri teria.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 628.3.7.12. Severe Gastrointestinal Adverse Events
Information about severe GI AEs as well as ant iemetic/antidiarrheal use will be collected in the 
eCRF/AE form.
8.3.7.13. Acute Renal Events
Renal safety  will be assessed based on repeated renal funct ional assessment as well as 
assessment of AEs suggest ive of acute or worsening of chronic renal failure.  GI AEs may lead 
to dehydration, which could cause a deterioration in renal funct ion, including acute renal failure.  
Patients shoul d be advised to notify invest igators in case of severe nausea, frequent vomit ing, or 
symptoms of dehydrat ion.
8.4. Treatment of Overdose
For this study, any dose of study druggreater than the highest possible dose (15 mg) and 
estimated from where the patient is in the dose -escalation regimen or treatment-maintenance 
regimen within a 2-daytime period will be considered an overdose and should be reported as an 
AE.  For example, if a patient is in the second mo nth of the dose -escalation period, the presum ed 
dose is 5 mg.  A patient who takes presumed 5 mg inject ions 1 day apart woul d not be 
considered to have an overdose.  However, if the patient was in the fourth month of dosing, was 
taking the presumed dose of 10 mg, and took injections 1 day  apart, the patient would have 
received a presumed dose of 20 mg within 2 days and would be considered to have had an 
overdose.
In the event of an overdose, the investigator/treating physician should:
1.Contact the Medical Monitor immediately.
2.Closely monitor the parti cipant for any  AE/SAE and laboratory  abnormalities for at least 
1 week.  Based on the AE profile o f tirzepatide, the fo llowing are the possible AEs 
related to an overdose:
a.Severe GI events that lead to dehy dration and require medical intervention.
b.CV abnorm alities such as increaseinheart rate, decrease in BP, supraventricula r 
arrhythmias/cardiac conduct ion disorders.
c.Hypoglycemia .
3.Implement m edical intervention/mo nitoring according to the clinical presentation .
4.Obtain a plasma sample for PK analysis as soon as possible from the date of the last dose 
of study intervention if requested by  the Medical Monitor (determined on a case-by- case 
basis).
5.Document the quanti ty of the excess dose as well as the duration of the overdose in the 
CRF.
Decisions regarding dose interruptions or modifications will be made by the invest igator in 
consultation wit hthe Medical Monitor based on the clinical evaluat ion of the participant.
8.5. Pharmacokinetics
Pharmacokinet icsamples will be obtained from  all patients.  Plasma tirzepatideconcentrati ons 
will be determined from blood samples obtained from patients randomized to tirzepatide 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 63treatment at the visits and times specified in the SoA(Section 1.3).  At each PK visit, the pati ent 
will be assigned to 1of the 2PK sampling windows (1 to 24 hours or 24 to 96 hour postdose) via 
IWRS.  In addition, a PK sample will be obtained at each immunogenicit y visit.  For all PK 
samples, the actual date and 24 -hour clock time of each sample will be recorded.   
Drug concentration informat ion that would unblind the study  will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
Concentration of t irzepatidewill be assayed using a validated method .
Bioanalytical samples collected to m easure invest igational product concentration will be retained 
for a maximum of 1 year following last participant visit for the study .
8.6. Pharmacodynamics
Samples to assess the p harmacodynamic (PD) properties of tirzepatide are included in the 
efficacy measures and associ ated subsections(Section 8.1).    
8.7. Genetics
8.7.1. Whole Blood Samples for Pharmacogenetic Research
A whole bloodsample will be collected for pharmacogenet ic analysis as specified in the S oA
(Section1.3) where local regulat ions allow.  
Samples will notbe used to conduct unspecified disease or populat ion genetic research either 
now or in the future.  Samples will be used to investigate variab le response to tirzepatideand to 
investigate genet ic variants though t to play a role in NASH.  Assessment of variable response 
may include evaluation o f AEs or differences in efficacy.  
All samples will be coded with the patientnumber.  These samples an d any data generated can 
be linked back to the patient only by the invest igator site personnel.  
Samples will be retained at a facilit y selected by  Lilly or its designee for a m aximum of 15years 
after the last participant visit for the study , or for a shorter period if local regulations and/or 
ethical review boards ERBs/ IRBsimpose shorter time limits.  This retention period enables use 
of new techno logies, response to regulatory  questions, and investigation o f variable response that 
may not be observed u ntil later in the development of tirzepatideor after tirzepatidebecome(s) 
commercially  available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches i nclude who le genome or exome 
sequencing, geno me wide association stud ies, and candidate gene studies .  Regardl ess of 
technology utilized genoty ping data generated will be used only for the specific research scope 
described in this sect ion.
8.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, PD, mechanism of act ion, variabilit y of participantresponse (including safet y), and 
clinical outcome.  Sample co llection is incorporated into clinical stu dies to enable examinat ion of 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 64these questions through measurement of bio molecules including DNA, proteins, lipids, and other 
cellular elements.
Samples for bi omarker research will be co llected at the times specified in the S oA(Section1.3)
where local regulat ions allow.
Samples will be used for research on the drug target, disease process, variable response to 
tirzepatide, pathways a ssociated with NASH, mechanism o f action of tirzepatide, and/or research 
method or i n validating diagnost ic tools or assay(s) related to NASH.  
All samples will be coded with the participant number.  These samples and any data generated 
can be linked back to the participant only by the investi gator site personnel.  
Samples will be retained at a facilit y selected by  Lilly or its designee for a m aximum 15 years 
after the last participant visit for the study , or for a shorter peri od if local regulations and ERBs 
impose shorter time limits.  This retention period enables use of new technologies, response to 
regulatory questions, and invest igation of variable response that may not be observed unt il later 
in the development of tirzepatideor after tirzepatidebecomes commercially  available.
8.9. Medical Resource Utilization and Health Economics
Health Economics and Medical Resource Utilizat ion parameters arenot evaluated in this study.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 659. Statistical Considerations
9.1. Statistical Hypotheses
The primary  hypothesis that i s being tested in this study is that tirzepatide 5 mg, 10 mg or 15 m g 
administered SC QW is superior to placebo with regards to resolut ion of NASH with no 
worsening of fibrosis at week 52 .
Major secondary  hypotheses are that tirzepat ide is superior to placebo with regards to
Regressio n of fibrosis with no worsening o f NASH at Week 52.
Prevention of fibrosis progression at W eek 52.
Decrease of NAS by ≥2 points at Week 52.
Absolute decrease in liver fat content by  MRI-PDFF at Week 52.
Decrease in body weight at Week 52.
9.2. Sample Size Determination
Approximately , 196participants will be randomized to placebo, tirzepatide 5 mg, tirzepatide
10mg, or tirzepatide 15 mgin a 1:1:1 :1ratio;assuming a 20% dropout rate , thisresultsin 
approximately  40completers per arm. Sample size selection is guided by the objective of 
establishing superiorit y of each tirzepatidedose to pl acebo relative to the proportion of 
participants achieving NASH resolut ion withoutworsening of fibrosis at 52weeks fro m 
randomization. The evaluat ion of superiorit y to placebo will be conducted for each of the 
3tirzepatide doses at 2 -sided significance level o f 0.05 using a test of 2proportions. The 
tirzepatide group mean response rate is assumed to be 42.5% andthe placebo group mean 
response rate is assumed to be 12.5%. The chosen sample size provides at least80% power to 
establish superiorit y of tirzepatide 5mg, tirzepatide 10mg,or tirzepatide15mg doses to 
placebo. No adjustment for multiplicity will be perform ed.
9.3. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Screened All participants who sign informed consent .
Randomized All participants who are randomly assigned to a treatment arm .
Efficacy analysis set (EAS) Data obtained during treatment period from all randomized participants who take 
at least 1 dose of double -blind study  treatment for at least 46 weeks and havea 
post-baseline liver biopsy that is collected within 2 weeks of the last dose of 
study treatment. Dataexcludes data after discontinuation of study drug. 
Participants will be included in the treatment group to which they were 
randomized.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 66Population Description
Exploratory analysis set (EXAS) Data obtained during treatment period from all randomized pa rticipants who take 
at least 1 dose of double -blind study  treatment for at least 36 weeks and have a 
post-baseline liver biopsy that is collected within 2 weeks of the last dose of 
study treatment . Data after discontinuation of study drug will be excluded . 
Participants will be included in the treatment group to which they were 
randomized.
Full analysis set (FAS) Data obtained during treatment period from all randomized participants who 
take at least 1 dose of double -blind study  treatment, regardless of adherence to 
study drug or having post -baseline liver biopsy.   Participants will be included in 
the treatment group to which they were randomized.
Safety analysis set (SS) Data obtained during treatment period plus safety follow -up period from all 
randomized participants who take at least 1 dose of double -blind study  
treatment, regardless of adherence to study drug or having post -baseline liver 
biopsy. Participants will be included in the treatment group to which they were 
randomized.
9.4. Statistical Analyses
9.4.1. General Statistical Considerations
Statistical analyses of this study  will be the responsibilit y of Lilly or its designee .
Any change to the data analyses methods described in the protocol will require an amendment 
ONLY if it changes a pr incipal feature of the protocol.  Any  other change to data analyses 
methods described in the protocol, and the just ification for making the change, will be described 
in the statistical analysis plan (SAP) or the clinical study report (CSR).  Additional exploratory 
analyses o f the data will be conducted as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f
0.05, and the confidence interval (CI) will be calculated at 95%, 2- sided. In statistical
summaries and analyses, patients will be analyzed as rando mized.
The Cochran -Mantel-Haenszel (CMH)test will be used to make comparisons amo ng treatment 
groups for the efficacy analyses of the primary endpoint and all other endpo ints that are 
measured as proportions. The analyses will adjust for stratification factors in the study.
Summary  statistics for other categorical measures (including categorized cont inuous measures) 
willinclude sample size, frequency , and percentages. Comparisons betwe en treatment groups 
for such variables maybe assessed using Pearson’s Chi-squaredtest.
The summary statistics for continuous measures will include sample size, mean, SD, median,
minimum, and maximum , andfor categorical measures will includesample size, frequency, and 
percentage .Theanalysis model to make comparisons among treatment groups relative to 
continuous measurements assessed over time (in addition to the baseline and end of treatment 
measurements) will be a mixed model for repeate dmeasures (MMRM ).
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 679.4.2. Treatment Group Comparability
9.4.2.1. ParticipantDisposition
Frequency counts and percentages of all pat ients screened, rando mized, and receiving at least 
1dose of study  drug will  be presented by  treatment groups. A listing of rando mized pat ients not
receiving study  drug will be provided. All patients who discontinue the study  will be identified, 
and the extent of their participat ion in the study  will be reported .  If known, a reason for their 
discontinuat ion will be given. Theprimary reaso ns for discontinuation will be listed and will be 
summarized by  treatment. Thepercentage of patients discont inuing fro m each treatment will be 
compared using the Fish er’sexact test.
9.4.2.2. Participant Character istics
Demographics, medical history , and concomitant illness will be summarized by treatment group
using the full FAS. 
9.4.2.3. Concomitant Therapy 
Concomitant medicat ions, including previous therapy  for diabetes, will be summarized by  
anatomical therapeut ic chemical classificat ion and treatment group u sing the FAS. In particular, 
the incidence of rescue therapy for severe, persistent hyperglycemia will be analyzed as an 
exploratory  safety endpoint. Dose modificat ions of oral  antihyperglycemic therapy  will also be 
compared between treatment groups. 
9.4.2.4. Treatment Discontinuation
Treatment discontinuationwill be listed using the FAS. Of the patients in the FAS, frequency 
counts and percentages of patientsdiscontinuing study drug, including the reason for 
discontinuat ion, will be presented by  treatment group.
9.4.2.5. Treatment Compliance
Treatment compliance is defined as taking at least 75% of required inject ions of study  drugwhile 
on study drug.  Frequency counts and percentages of patients compliant to study drug will be 
summarized by treatment arm using the FAS. 
9.4.3. Efficacy Analyses
9.4.3.1. Primary Analyses
The primary  efficacy analyses will be conducted to establish superiority of tirzepatide 5 mg, 
10mg or15 mg to placebo usingthe proportion of participants cl assified wi th absence of NASH 
with no worsening of fibro sis on liver histology ,as defined in Sect ion 8.1.1, in their post-
baseline biopsy .  The primary  analyses will  be perform ed on EASusing CMHtestthat compares 
treatment groups and placebo while adjusting for stratificat ion factors. Stratificat ion factors are 
T2DM status (Yes or No) and the region (Japan, US including Mexic o, and Europe including 
Israel).Details will be provided in the SAP. Participants with a missing post -baseline biopsy 
will be remo ved from the primary  analyses. 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 689.4.3.2. Secondary Analyses
In addition to the primary  efficacy analysis of NASH resol ution with no worsening of fibrosis in 
study population, the following secondary study objectiveswill be analyzed on the EAS:
Regressio n of fibrosis with no worsening o f NASH at Week 52.
Prevention of fibrosis progression at W eek 52.
Decreasing NAS by  ≥2 points at Week 52.
Decreasing liver fat content by MRI -PDFF at Week 52.
Decreasing body weight at Week 52.
Analyses for regression of fibrosis wi th no worsening of NAS H, prevent ion of fibrosis 
progression, and dec reasing NAS by  ≥2pointswill be conducted in a manner similar to the 
primary efficacy analyses di scussed in Sect ion 9.4.3.1.
Decreasing liver fat content by MRI -PDFFand body weightwill be analyzed by MMRM . The 
corresponding baseline value, treatment, visits, trea tment by visit interaction, and stratificat ion 
factorsare the terms in the MMRM analysis .
9.4.3.3. Tertiary/Exploratory Analyses
All exploratory efficacy analyses that require a post-baseline biopsy result will be done using the 
EAS. The rest of the analyses may be done using either the FASor EAS. Depending on the 
number of patients that drop out between Weeks36 and 46, primary , secondary ,and exploratory  
efficacy analyses may be repeated withthe EXAS. Details will be provided in the SAP.
9.4.4. Safety Analyses
The SSwill be used for safet y analyses. The overall co mparison of tirzepatidedosesversus 
placebo will  be reported for these safety analyses. Safety measures will include vital signs, body  
weight, TEAEs (including SAEs and AEs ofspecial interest), laboratory  measures (incl uding 
ADAs), and ECGs.
Summary  statistics will be presented by  treatment for the safet y measures. Counts and 
proportions of subjects experiencing AEs will be reported for each treatment group . Fisher’s 
exact test maybe used to com pare the treatm ent groups .
Adverse events will be coded from the actual term using the Medical Dict ionary for Regulatory
Activities (MedDRA) and reported with preferred terms and system organ class. 
9.4.5. Pharmacokinetic/Pharmac odynamic Analyses
The relationships between tirzepat ide dose, concentration and efficacy, tolerabilit y and safety 
measures will be characterized using population PK and PK/PD nonlinear mixed- effects 
modeling techniquesimplemented on Nonlinear Mixed Effects Modeling (NONMEM )software.  
Additionally, the impact of intrinsic and extrinsic factors (such as age, weight, sex, renal ,and 
hepatic functions) on PK and/or PD parameters may  be evaluated.  
If ADA titers are detected in the immunogenicit y samples, the i mpact of ti ters on tirzepatide PK 
and/or PD m ay be evaluated.   
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 699.4.6. Evaluation of Immunogenicity 
The frequency and percentage of participantswith preexisting ADA and with treatment-
emergentADA+ to tirzepatidewill be tabulated.  Treatment -emergent ADAs are defined as those 
with a titer 2-fold (1 dilution) greater than the minimum required dilut ion if no ADAs were 
detected at baseline (treatment -induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter 
compared to baseline if ADAs were detected at baseline (treatment -boosted ADA).  The 
minimum required dilut ion of the ADA assay is 1:10. For the treatment-emergent ADA+ 
participants,the distribution of maximum titers will be described.  The frequency of neutralizing 
antibodies,if performed, will also be tabulated in treatment-emergentADA+ participants.If 
cross-reactivity to native GLP -1 and GIP or neutralizing antibodies against native GLP- 1 and 
GIP assays are performed, the frequency o f each will be reported.
The relationship between the presenc e of antibodies and the PK parameters and PD response 
including safet y and efficacy  to tirzepatidemay be assessed.
9.4.7. Subgroup Analyses 
Subgroup analyses of important factors, including fibrosis stage, am ount of weight loss, baseline 
BMI, baseline liver fat content, T2DM status, and other factors to be specified in the SAP are 
planned for the key  outcomes. The models used for these analyses will vary  depending on the 
subgroups and the outcome. More details of the modeling will be provided in the SAP.   Other 
exploratory  subgroup analyses may be performed as deemed appropriate.
9.5. Interim Analyses 
A futility interim analysis based on 26-week liver fat reduction fro m baselinemeasured by 
MRI-PDFFwill be conducted .The study  will be stopped or modified if noneof the tirzepatide 
treatment arms meet the required criteria to continue the study .The trial will not be stopped 
based on the superiorit y of the treatm ent versus placebo.  Therefore, there will be no inflationof
the type 1 error rate and no need to emp loy an alpha spending function or mult iplicity 
adjustment.  The details regarding number of patients ,type of analysis, and success cri teriawill 
be provided in the assessment committee (AC) charter . In addition, other interim analyses may  
be conducted.   
An AC will be formed to review the interim analyses in an unblinded manner. Study team
members who have potential contact with the sites will remain blinded throughout the study .  
Information that may unblind the study  during the analyses will not be rep orted to study  sites or
blinded study  team members before the study  has been unblinded. Study sites will receive 
information about interim results onlyif deemed necessary  for the safet y of their patients. 
Details on the timing of the interim analyses an d unblinding will be specified in the unblinding 
plan.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 7010. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
oConsensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guideline s
oApplicable International Council for Harmonisation (ICH)Good Clinical Practice 
(GCP) Guidelines
oApplicable laws and regulations
The protocol, protocol amendments, ICF, I B, and other relevant documents ( for 
example, advertisements) must be submitted to an IRB/IEC by  the invest igator and 
reviewed and approved by the IRB/IEC before the study  is initiated.
Any amendments to the protocol will require IRB/IEC approval before implementation 
of changes made to the study  design, except for changes necessary  to eliminate an 
immediate hazard to study  participants.
The invest igator will be responsible for the fo llowing:
oProviding written summaries of the status of the study  to the IRB/IEC annually  or 
more frequently in accordance wit h the requirements, policies, and procedures 
established by  the IRB/IEC
oNotifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures
oProviding oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guideli nes, the IRB/IEC, European regulat ion 536/2014 
for clinical studi es (if applicable), and all other applicable local regulat ions
10.1.2. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
participant or h is/her legally authorized representative and answer all questions 
regarding the study .
Participants must be inform ed that thei r participation is voluntary.Participants or thei r 
legally authorized representative will be required to sign a statement of inf ormed 
consent that meets the requirements of 21 CFR 50, local regulat ions, ICH guidelines, 
Health Insurance Portabilit y and Accountabilit y Act (HIPAA) requi rements, where 
applicable, and the I RB/IEC or study center.
The medical record m ust include a statem ent that wri tten inform ed consent was 
obtained before the participant was enro lled in the study and the date the written 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 71consent was obtained. The authorized person obtaining the informed consent must also 
sign the ICF.
Participants must be re-consented t o the most current versio n of the ICF(s) during th eir 
participation in the study.
A copy of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
authorized representati ve.
For patient rescreening , see Secti on 5.4.  
10.1.3. Data Protection
Participants will be assigned a unique ident ifier by IWRS. Any participant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; part icipant 
names or any  information which would make the participant ident ifiable will not be 
transferred.
The participant must be inform ed that his/her personal  study-related data will  be used 
by the sponsor in accordance wit h local data protecti on law. The level of disclosure 
must also be explained to the participant.
The participant must be inform ed that his/her medical records m ay be examined by 
Clinical Qualit y Assurance auditors or other authorized personnel appo inted by the 
sponsor, by  appropriate IRB/IEC members, and by inspectors from regulatory  
authorities.
10.1.4. Dissemination of Clinical Study Data
Report Preparation
Aninvestigator will sign the final CSR for this study, indicat ing agreement that, to the best of his 
or her knowledge, the report accurately  describes the conduct and results of the study .
Public Access to Reports and Data
Reports
The sponsor will disclose a summary o f study information, including tabular study results, on 
publically  available websites where required by  local law or regul ation.
Data
The sponsor provides access to all individual participant data collected during the trial, after 
anonymizat ion, with the excepti on of PKor genetic data.  Data are available to request 6 months 
after the indicat ion studied has been approved in the US and European Unio n (EU)and after 
primary publication acceptance, whichever is later.  No expiration date of data requests is 
currently set once they  are made available.  Access is provided after a proposal has been 
approved by  an independent review commit tee identified for thi s purpose and after receipt of a 
signed data sharing agreement.  Data and documents, including the study  protocol, SAP, CSR, 
blank or annotated case report forms, will be provided in a secure data sharing environment for 
up to 2 years per proposal .  For details on submitt ing a request, see the instructions provided at 
www.clinicalstudy datarequest.com .
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 72Publications/Publication Policy
The publicat ion policy is described in the letters of agreement between the sponsor and the 
investigato rs and inst itutions.  
10.1.5. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provide instructi onal materi al to the study  sites, as appropriate
provide sponsor start- up training to instru ct the investigators and study  
coordinators.  This training will give instruction on the protocol, the complet ion 
of the CRFs, and study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, telephone, and/or fax
review and verify data reported to detect potential errors 
In addition, Lilly or its representatives will periodically check a sample of the participantdata 
recorded against source documents at the study  site.  The study  may be audited by Lilly or i ts 
representatives and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
documents.
Data Capture System
The invest igator is responsible for e nsuring the accuracy , completeness, l egibility, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem (EDC) will be used in this study  for the collect ion of eCRF 
data.  The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  The invest igator is responsible for the 
identification of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the eCRF.
Additionally, clinical outcome assessment data (questionnaires and diary data) will be co llected 
by the investigator site personnel, via a paper source document and will be transcribed by the 
investigator site personnel into the EDC system .
Data collected via the sponsor -provided data capture system will bestored at thi rd-party. The 
investigator will have cont inuous access to the data during the study  and until decommissioning 
of the data capture sy stem.  Prior to decommissio ning, the invest igator will receive an archival 
copy of pertinent data for retention.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 73Data managed by  a central vendor, such as laboratory  test data, will be stored electronically  in 
the central vendor’s database system and reports/electronic transfers will be provided to the
investigator for review and retention.  Data will subsequent ly be transferred fro m the central 
vendor to the Lilly data warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem.
10.1.6. S ource Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the invest igator’s site.
Data entered in the eCRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The invest igator 
may need to request previous medical records or transfer records, depending on the 
study. Also, current medical records must be available.
Definition of what constitutes source data can be found in Section 10.1.5.
10.1.7. Study and Site Closure
10.1.7.1. Discontinuation of the Study
The study  will be discontinued if Lilly or its designeejudges it necessary  for medical, safet y, 
regulatory, or other reasons consistent with applicable laws, regulat ions, and GCP.
Medical Oversight and Safety Review
Ongoing safety review(s) by  designated sponsor personnel will occur and be documented.  Such 
reviews will include: 
Monitoring and assessing the safety  information collected during the trial both in real 
time and periodically
Reviewing safety  data for tren ds that need action 
Detecting adverse drug/device effects.
A safety investigation will be triggered to determine if the study  should be terminated early  
based on the fo llowing criteria:
Two study  participants develop the same TEAE or SAE considered possibly or 
probably related to study  drug that i s severe or m edically significant but not 
immediately  life-threatening; or where hospitalizatio n or prolongat ion of 
hospitalization is indicated; or is disabling; or limit s self-care activities of daily livi ng.
One study  participant develops any TEAE or SAE regardless of attribut ion to study  
drug that has l ife-threatening consequences or requires urgent intervention
Death of any study  participant at any  time
Any other clinically  significant safet y signal
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 7410.1.7.2. Discontinuation of Study Sites
Study site participation may be discont inuedif Lilly or its designee, the investigator, or the ERB 
of the study  sitejudges it necessary for medical, safety, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
10.1.8. Publication Policy
The results of this study  may be published or presented at scient ific meetings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to the sponsor 
before submissio n. This allows the sponsor to protect proprietary  information and to 
provide comments.
The sponsor will co mply with the requirements for publication o f study results. 
Authorship will be determined by  mutual agreement and in line wit h Internat ional 
Committee of Medical Journ al Editors authorship requirements.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 7510.2. Appendix 2: Clinical Laboratory Tests
The tests detailed belowwill be performed by the central laboratory unless otherwi se 
stated.
Local laboratory  results are only  required in the event that the central laboratory  results 
are not available in t ime for response evaluat ion.  If a local sample is required, it is 
important that the sample for central analysis is obtained at the same 
time.Additionally, if the local laboratory  results are used to m ake either a study  
intervention decision or response evaluat ion, the results must be entered into the CRF.
Protocol-specific requirements for inclusio n or exclusio n of participants are detailed in 
Section5of the protocol.
Additional tests may be performed at any  time during the study  as determined necessary  
by the investigator or required by  local regulations.
Refer to Section 5.1(Inclusion Criteria) for screening pregnancy  criteria.  
Investigators must document their review of each laboratory  safety report.
Laboratory /analyte results that coul d unblind the study  will not be reported to invest igative sites 
or other blinded personnel until the study  has been unblinded.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 76Clinical Laboratory Testsa
Hematology Clinical Chemistry
Hemoglobin Sodium
Hematocrit Potassium
Erythrocyte count (RBC) Total bilirubin
Mean cell volume Direct bilirubin
Mean cell hemoglobin concentration GGT
Leukocytes (WBC) ALP
Neutrophils, segmented ALT
Lymphocytes AST
Monocytes BUN
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Total protein
Hemaglobin A1c Albumin
Glucose
Coagulation Pancreatic a mylase
Prothrombin time Lipase
Prothrombin time ,INR
Special Chemistry
Urinalysis Thyroid stimulating ho rmone (TSH)b
pH Transferrin saturationb
Protein Calcitonin
Glucose
Blood Hormones (females)
Leukocyte esterase Pregnancy test, serumb,cand/or urinec
Urine Chemistry Estradiolb,d
Albumin FSHb,d
Creatinine Luteinizing hormone (LH)b,d
Lipid Panel Serologyb,e
Total cholesterol Hepatitis B Surface Ag
HDL-C HIV (human immunodeficiency virus )
LDL-C
TriglyceridesHepatitis C Ab (or virus RNA for patients cured of   
hepatitis C to confirm absence of virus)
BiomarkersfImmunogenicityf
Free Fatty Acid Anti-tirzepatide antibodies
K-18 Anti-tirzepatide antibody neutralization
Ferritin
Pro-C3 Pharmacogenetics Stored Sampleb
Insulin Nonpharmacogenetic Stored Samples
C-peptide EDTA plasma
ELF (procollagen III amino terminal peptide, 
hyaluronic acid, tissue inhibitor 
metalloproteinase type 1)Serum
P800plasma
Adiponectin (Total and HMW) Pharmacokinetic Samplesf,g
NIS4 (alpha-2-macroglobulin, chitinase -3-like 
protein 1, HbA1c, and microRNA -34a)Calculations
UACR
eGFR (calculated by CKD -EPI equation)
Optional urine drug screen (local, at the 
discretion of the investigator )FIB-4h(ALT, AST, platelets)
FAST score (CAP, LSM, AST)
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 77Abbreviations:  Ab = antidrug antibody; Ag = antigen; ALP = alkaline phosphatase; ALT = alanine 
aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; CAP = controlled attenuation 
parameter ;CKD-EPI = chronic kidney disease epidemiology collaboration; EDTA = ethylenediaminetetraacetic 
acid; ELF = enhanced liver fibrosis; eGFR = estimated glomerular filtration rate; FIB-4 = fibrosis -4;FSH = 
follicle stimulating hormone; GGT=Gamma-glutamyl transferase; HDL-C = high density lipoprotein 
cholesterol; HIV = human immunodeficiency virus; HMW = high molecular weight; INR = international 
normalized ratio ; IWRS = interactive web response system; LDL-C = low density lipoprotein cholesterol; 
LSM=liver stiffness measurement; NIS4 = noninvasive score 4 ; RBC = red blood cells; UACR = urine albumin 
to creatinine ratio; WBC = white blood cells.
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted.
bScreening only .
cSerum pregnancy test will be performed by the central laboratory at Visit 1 for women of child -bearing potential.  
A local urine pregnancy test should be given to all women of child -bearing potential at Visit 3 prior to 
administration of first dose of study drug to confirm lack of pregnancy. For the remainder of the study, a urine 
pregnancy test may be performed locally at the investigator’s discretion if pregnancy is suspected during the 
study.
dCollect serum estradiol, FSH, and LH in women whose menopausal status needs to be determined.  For 
participants known to be either premenopausal or postmenopausal, these tests do not need to be collected.
eScreening laboratory tests also include serum hepatitis B surface Ag, hepatitis C antibody (Ab) , and HIV (human 
immunodeficiency virus )Ab tests for all participants.  Participants treated for hepatitis C should have a hepatitis 
C RNA test rather than an antibody test .
fResults will notbe providedto the investigative sites.
gPharmacokinetic (PK) samples for immunogenicity should be collected prior to dose administration.  At 
specified visits, additional PK samples will be collected after dosing at a schedule determined by IWRS for 
individual patients.
hFIB-4 will be calculated by the central lab oratory.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 7810.3. Appendix 3: Liver Safety: Actions and Follow -Up Assessments
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may 
be required in fo llow-up with participantsin consultat ion with the Lilly, or i ts designee,clinical 
research physician /clinical research scient ist(CRP/CRS) .
The initial panel o f tests are shown below.  
Based on the patient’s history  and initial results, further testing may be considered, in 
consultation wit h the Lilly CRP/CRS , including t ests for hepatitis D virus , cytomegalovirus, 
Epstein Barr virus , acetaminophen levels, acetaminophen protein adducts, urine toxicology  
screen, Wilson’s disease, blood alcoho l levels, urinary  ethylglucuronide, and serum 
phosphatidylethanol.   These addit ional tests shoul d be perform ed through l ocal laboratories.
Based on the circumstances and the invest igator’s assessment of the participant’s clinical 
condition, the invest igator should consider referring the participant for a 
hepatologist/gastroenterologist consultation, magnetic resonance cho langiopancreatography , 
endoscopi c retrograde cholangiopancreatography , cardiac echocardi ogram, or a liver biopsy.  
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocytes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti-nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti-smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase ; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssayed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 7910.4. Appendix 4:  Definitions of Hypoglycemia
Investigators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an episode considered to be related to hy poglycemia (the BG values in this sect ion refer to values 
determined by a laboratory  or Internati onal Federati on of Clinical Chemistry andLaboratory  
Medicine blood -equivalent glucose meters and strips) in accordance with the 2017 American 
Diabetes Association posit ion statement on glycemic targets (ADA 2017).
Glucose Alert Value (Level 1):
-Documented symptom atic hypoglycemia is defined as any t ime a participant feels 
that he or she is experiencing symptoms and/or signs associated with hypoglycemia 
and has a BGlevel of ≤70 mg/dL (≤3.9 mmo l/L)
-Documented asymptom atic hypoglycemia is defined as any event not accompanied 
by typical symptoms of hypoglycemia but with a measured BG ≤70 mg/dL 
(≤3.9mmol/L)
-Documented unspecified hypoglycemia is defined as any  event with no information 
about symptoms of hypoglycemia available but with a measured BG ≤70 mg/dL 
(≤3.9mmol/L)
Clinically Significant Hypoglycemia (Level 2):
-Documented symptom atic hypoglycemia is defined as any time a participant feels 
that he or she is experi encing symptom s and/or si gns associ ated with hypoglycemia 
and has a BG level o f <54 mg/dL (<3.0 mmol/L)
-Documented asymptomat ic hypoglycemia is defined as any event not accompanied 
by typical symptoms of hypoglycemia but with a measured BG <54 mg/dL 
(<3.0mmol/L)
-Documented unspecified hypoglycemia is defined a s any event with no informat ion
about symptoms of hypoglyce mia available but with a measured BG <54 mg/dL 
(<3.0mmol/L).
Severe hypoglycemia (Level 3):
-Severe hypoglycemia is defined as an ep isode with severe cognit ive impairment 
requiring the assistance of another person to actively  administer carbohydrate, 
glucagon, or other resuscitative act ions.  These episodes may  be associated with 
sufficient neuroglycopenia to induce seizure or coma.  B lood glucose measurements 
may not be available during such an event, but neurological recovery attributable to 
the restoration of BG to normal is considered sufficient evidence that the event was 
induced by  a low BG concentrati on.
Nocturnal hypoglycemia:
-Nocturnal  hypoglycemia is defined as any hypoglycemic event that occurs between 
bedtime and waking.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 8010.5. Appendix 5:  World Health Organization Standardized Protocols for 
the Measurement of Height and Weight
The following inform ation has been adapted fro m standardized physical measurement protocols 
for the Worl d Health Organizati on’s STEPwi se approach to Surveillance (STE PS) (WHO 2017).
Measuring Height
Step 1Ask the pati ent to rem ove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by the patient at every clinic visit when 
their heightis measured).
Step 2Askthe patient to stand on the calibrated height measuring board (stadio meter) or against 
a wall wit h their feet together and their knees straight with their heels against the back board or 
the stadiometer or the wall.
Step 3Ask the pati ent to look straightahead without tilt ing their head up.
Step 4Ask the pati ent to breathe in and stand tall. If using a stadiometer or fixed measuring 
device, move the device’s measurement arm gent ly down onto the top of the patient’s head. 
Record the patient’s height in centimeters (cm).
Measuring Weight
Body weight m easurements shoul d be done in a consistent manner using a calibrated electronic 
scalecapable of measuring weight in kilo grams (kg) to one decimal place . All weights for a 
given patient should be measured us ing the same scale, whenever possible, after the patient has 
emptied their bladder. Patients should be light ly clothed but not wearing shoes while their 
weight is measured.
Step 1 Ask the pati ent to rem ove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by the patient at every clinic 
visit when their weight is measured).
Step 2 Make sure the scale is placed on a firm, flat, even surface (not on carpet or on a 
sloping surface or a rough uneven surface).
Step 3 Ask the pati ent to step on to the scal e with one foot on each si de of the scale.
Step 4 Ask the pati ent to stand still wit h their arms by their sides and then record their 
weight in kilograms (kg).
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 8110.6. Appendix 6:Diet and Physical Activ ity Suggestions for Sites without 
Programs
10.6.1. Diet
Diet recommendat ions are based on the World Healt h Organizat ion (WHO 2018) for every one 
and a consensus report fro m the American Diabetes Associat ion and the European Associat ion 
for the Study  of Diabetes (Da vies et al. 2018) for treatment of hyperglycemia, all o f which are 
based on a Mediterranean eat ing pattern .
The Mediterranean eating pattern for a healthy diet consist of:
Legumes (e.g. ,lentils and beans)
Nuts
Whole grains (e.g. ,unprocessed wheat, maize, millet, oats, and brown rice)
At least 5 portions of fruit and vegetables per day  (excluding potatoes, sweet potatoes, 
cassava, and other starchy  roots)
Less than 10% of total energy  intake from free sugars (equivalent to 50 g or 12 level 
teaspoons), but ideally less than 5% of total energy intake.  Free sugars are sugars added 
to foods and drinks, as well as sugars present in honey, sy rups, fruit juices, and fruit j uice 
concentrates.
Less than 30% of total energy  intake from fats. Unsaturated fats are preferred over 
saturated fats. Unsaturated fats are found in fish, avocado, nuts, and in sunflower, cano la, 
and olive oils.  Consumption of saturated fats, which are fats in fatty meat, butter, palm 
and coconut oil, cream cheese, g hee, and lard, should be reduced to less than 10% of total 
energy intake.  Trans -fats, which are found in industrially produced foods, should be 
avoided.
Salt intake shoul d not be m ore than 5 g (about 1 teaspoon) per day  and shoul d be iodized.
Although the Mediterranean eat ing pattern does not prohibit alcoho l, particularly red wine, 
patients with NASH shoul d be encouraged to reduce or eliminate alcohol intake due to the 
effects of alcoho l on the liver.
10.6.2. Physical Activity
Regular physical act ivity can improv e a patient’shealth. Moving more and sitting less have 
benefitseveryone, regardless of age, sex, race, ethnicit y, or current fi tness level. Benefits 
accumulate with even small amounts and start immediately.  
To safely engage in physical act ivity, types of physical act ivity appropriate for the patient’s 
current fitness should be chosen.  Furthermore, the amount and duration of physical act ivity 
should be gradually increased over time.  Patients with chronic condit ions and symptoms should 
be under the ca re of a healt h care provider about the ty pes and amounts of physical act ivity that 
are appropriate for the patient.
Physical act ivity recommendations are based on WHO recommendat ions (WHO 2018) and also 
align with the ADA and European Associ ation for the Study of Diabetes consensus report 
(Davies et al. 2018) and with the US Health and Human Services (HHS 2019) recommendat ions. 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 82Any physical act ivity is better than none.  Adults should move more and sit less.
Adults should do 150 minutes (2 hours 30 minutes ) to 300 minutes (5 hours) of 
moderate-intensity aerobic physical  activity throughout the week or 75 minutes (1 hour 
15 minutes) to 150 minutes (2 hours and 30 minutes) a week of vigorous- intensity 
aerobic physical act ivity, or an equivalent combination of moderate-and 
vigorous-intensity aerobic activity. Preferably, aerobic activity should be spread 
throughout the week. 
Aerobic act ivity should be performed in bouts of at least 10 minutes duration.
For additional health benefits, adults should increase t heir moderate -intensity aerobic 
physical act ivity to 300 minutes per week, or engage in 150 minutes of vigorous -intensity 
aerobic physical act ivity per week, or an equivalent combinat ion of moderate -and 
vigorous-intensity activity. Additional health benefits are gained by  engaging in physical 
activity beyond the equivalent of 300 minutes (5 hours) of moderate -intensity physical 
activity a week.
Muscle-strengthening act ivities should be done involving major muscle groups on 2 or 
more days a week.
Older adults, with poor mobility, should perform  physical act ivity to enhance balance and 
prevent falls on 3 or more days per week , as well as aerobic and muscle -strengthening 
activities.  They should be as physically act ive as their abilit ies and condit ions allow.  
When older adults cannot do 150 minutes of moderate -intensity aerobic activity a week 
because of chronic condit ions, they should be as physically act ive as their abilit ies and 
conditions allow.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 8310.7. Appendix 7:Medical Device Incidents: Definition and Procedures 
for Recording, Evaluating, Follow-Up , and Reporting
Definitions of a Medical Device Incident
The detecti on and docum entation procedures described in this protocol apply  to all sponsor 
medical devices provided for use in the stud y.
Medical Device Incident Definition
A medical device incident is any malfunct ion or deteri oration in the characteri stics 
and/or performance of a device as well as any inadequacy  in the labeling or the 
instructions for use which, direct ly or indirect ly, might lead to or might have led to the 
death of a participant/user/other person or to a serious deterioration in his/her state of 
health.
Not all incidents lead to death or serious deterioratio n in health. The nonoccurrence of 
such a result might have been due to other fo rtunate circumstances or to the intervent ion 
of health care personnel.
It is sufficient that:
An incidentassociated with a device happened.
AND
The incidentwas such that, if it occurred again, might lead to death or a serious 
deterioration in health.
A serious deteri oration in state of health can include any  of the following:
Life-threatening illness
Permanent impairment of body  function or perm anent dam age to body  structure
Condition necessitat ing medical or surgical intervent ion to prevent one of the above
Fetal distress, fetal death, or any  congenital abnormali ty or birth defects
Examples of Incidents
A participant, user, caregiver, or health care professional is injured as a result of a medical 
device failure or its misuse.
A participant’s study  intervention is interrupted or compromised by  a medical device failure.
A misdiagnosis due to medical device failure leads to inappropriate treatment.
A participant’s healt h deteriorates due to medical device failure.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 84Documenting Medical Device Incidents
Medical Device Incident Documenting
Any medical device incident occurring during the study will be documented in the 
participant’s m edical records, in accordance wit h the invest igator’s normal clinical pract ice, 
and on the appropriate form of the CRF.
For incidents fulfilling the definit ion of an AE or an SAE, the appropriate AE/SAE CRF page 
will be co mpleted as described in Section 8.3.
The CRF wil l be completed as thoroughly as possible and signed by the invest igator before 
transmittal to the sponsor or designee.
It is very important that the investigator provides his/her assessment of causalit y (relationship 
to the medical device provided by  the sponsor)at the time o f the initial AE or SAE report and 
describes any  corrective or remedial act ions taken to prevent recurrence of the incident.
A remedial act ion is any action other than routine maintenance or servicing o f a medical 
device where such act ion is necessary to prevent recurrence of an incident. This includes any  
amendment to the device design to prevent recurrence.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 8510.8. Appendix 8:Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Child -Bearing Potential (WOCBP)
A woman is considered fertile fo llowing menarche and unt il becoming postmenopausal unless 
permanently sterile (See below).
If fertility is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervention, additional evaluation should be considered.
Women in the following categori es are not considered WOCBP
1.Premenarchal
2.Premenopausal  female with 1 of the following:
Documented hysterectomy
Documented bilateral  salpingectomy
Documented bilateral  oophorectomy
For individuals wit h permanent infert ility due to an alternate medical cause other than the 
above,(e.g., mullerian agenesis, androgen insensit ivity), investigator discret ion should be 
applied to determin estudy entry.
Note: Documentation can co me from the site personnel’s :review of the participant’s 
medical records, medical examinat ion, or medical history  interview.
3.Postmenopausal  female
A postmenopausal  state is defined as no menses for 12 months without an alternat ive 
medical cause. 
A high follicle stimulat ing hormone (FSH) l evel in the postm enopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy  (HRT). However, in the 
absence of 12 months of amenorrhea, confirmat ion with more than one FSH 
measurement >40 IU/L or mIU/mL is required. 
Females on HRT and whose menopausal status is in doubt will be required to use one 
of the nonestrogen hormonal highly effect ive contraception methods if they wish to 
continue their HRT during the study . Otherwise, they must discont inue HRT to allow 
confirmat ion of postmenopausal status before study enrollment.
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy  information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study . This 
applies only to male participants who receive study intervention.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 86After obtaining the necessary  signed informed consent from the pregnant female partner 
directly, the invest igator will record pregnancy information on the appropriate form and 
submit it to the sponsor within 24 hoursof learning of the partner’s pregnancy .The female 
partner will also be fo llowed to determine the outcome of the pregnancy. Information on the 
status of the mother and child will be forwarded to the sponsor. Generally, the fo llow-up 
will be no longer than 6 to 8 weeks following the estimated delivery date. Any terminat ion 
of the pregnancy  will be reported regardless of fetal status (presence or absence of 
anomalies) or indicat ion for the procedure. 
Female participants who become pregnant
The invest igator will co llect pregnancy information o n any female participant who becomes 
pregnant while part icipating in this study. Information will be recorded on the appropriate 
form and submi tted to the sponsor wi thin 24 hours of learning of a participant ’s pregnancy . 
The participant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect follow-up inform ation on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, fo llow-up will not be requi red for 
longer than 6 to 8 weeks beyond the estimated delivery date. Any terminat ion of pregnancy  
will be reported, regardless of fetal status (presence or absence of ano malies) or indicat ion 
for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  complication 
or elective terminat ion of a pregnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any poststudy 
pregnancy -related SAE considered reasonably  related to the study  intervention by the 
investigator will be reported to the sponsor as described in Section8.3.2.  While the 
investigator is not obligated to actively seek this informat ion in former study participants, he 
or she may learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will 
discontinue study  interventionor be withdrawn from the study .
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 8710.9. Appendix 9:  List of Prohibited Medications by Protocol Section
Protocol Section Prohibited Medication
5.2. Exclusion Criteria
Medical Conditions
  #28
Prior/Concomitant Therapy
  #51
  #52
  #53
  #54
  #55
  #56
  #57Marijuana and CBD oil
Insulin –Long-term treatment
GLP-1 Receptor Agonists
Drugs associated with hepatic steatosis(amiodarone, methotrexate, 
tamoxifen)
Medications associated with weight gain unless on stable dose.  Note –
examples such as atypical antipsychotics are included in the 
investigator training materials.
Long term systemic glucocorticoids
Weight loss drugs and weight loss herbal supplements.  These include, 
but are not limited to:  Saxenda [liraglutide 3.0 mg], Alli®/Xenical® 
[orlistat], Meridia® [sibutramine], Acutrim® [phenylpropanolamine], 
Sanorex® [mazindol], Apidex® [phentermine], BELVIQ® 
[lorcaserin], Qsymia™ [phentermine/topiramate combin ation], 
Contrave® [naltrexone/bupropion].
Anticoagulants (other than aspirin or NSAIDs) that may increase the 
risk of bleeding with the liver biopsy
6.5.1.2 Hyperglycemia Rescue 
MedicationDose increases of the following are NOT allowed during the study:  
SGLT-2 inhibitors
TZDs
Initiation of the following is NOT allowed during the study:
GLP-1 receptor agonists
DPP-4 inhibitors   
SGLT-2 inhibitors
TZDs
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 8810.10. Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances
Implementation of this appendix
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by the sponsor in partnership wit h the 
investigator.
Exceptional circumstances
Exceptionalcircumstances are rare events that may cause disruptions to the conduct of the study .
Examples include pandemics or natural disasters .  These disrupt ions may limit the abilit y of the 
investigators, participants, or both to attend on -site visits or to conduct pl anned study  procedures.
Implementing changes under exceptional circumstances
In an except ional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by local regulat ions. 
After approval by local Ethical Review Boards, regulatory  bodies and any  other relevant l ocal 
authorities, implementation of except ionalcircumstance changes will not ty pically requ ire 
additional notification to these groups, unless they  have specific condit ions in which notificat ion 
is required .To protect the safetyof study participants, urgent changes may be implemented 
before approval, but need tobe reported as soon as possible . All approvals must be retained in 
the study records.
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance,if needed. 
Considerations for making a change
The prevailing considerat ionfor making a change is e nsuring the safet y of study participants.
Additional important considerat ions for making a change are compliance with Good Clinical 
Practice, enabling participants to continue safely  in the study , and maintaining the integrit y of the 
study. 
Informed consent
Additional consent fro m the participant will be obtained , if required, for:
participation in remote visits, as defined in Section “Remote visits,”
dispensation of addit ional study interventionduring an extended treatment period, 
alternate delivery  of study intervention and ancillary  supplies, and
provision of their personal  or medical  information required prior to implementation of 
these activit ies. 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 89Changes in study conductduring exceptional circumstances
Changes in study  conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed .
The following changes in study  conduct will not be considered protocol deviat ions.
1.Remote visits
Remote visits only apply to Visit 4 through Vi sit 13, and follow -up visits.  Every effort shoul d be 
made for the participantsto return to on -site visits as soon as reasonably  possible, while ensuring 
the safety of the participantsand invest igational sitestaff.  The study  site shouldcapture the 
method of data collecti on and procedure conduct with a specific explanat ion for any data missing 
in the source docum entdue tomissed in -person sit e visits.
Regardless of the ty pe of remote visits implemented, the protocol r equirements regarding the 
reporting of AEs, SAEs, and product complaints remain unchanged .
Any procedures that cannot be accomplished at a remote visit should be conducted at the next 
on-site visit and captured as a protocol deviation related to the except ional circumstances.  Of 
note, procedures from the missed visit that were not collected and are the same as ones at the 
next site visit do not need to be duplicated.  However, imaging procedures (Fibroscan and MRI) 
scheduled for Visit 10 (Week 26) should be collected as close to the schedule aspossible.  
Electrocardiogram s scheduled for Visit 10 (Week 26) should be collected locally  and reviewed 
by the investigator for patient safet y; however, centralized ECGs should be co llected at the next 
on-site visit. 
Mobile healthcare:
Healthcare visits may be perform ed by a mobile heal thcare provi der at locations other 
than the study  site when parti cipants cannot travel to the site due to an except ional 
circumstance if written approval is provided by  the sponsor .Procedures performed at 
such visit s include, but are not limited to : 
Weight measurement
Collecting blood sam ples
Brief physical assessment or general  wellness check
Efficacy measures and safet y assessments
Patient-reported outcome measures administrati on
Collecting health information
Other alternative locations :
During exceptional circumstances, laboratory  samples may be drawn locally , if needed 
outside of mobile heal thcare visits.
2.Local laboratory testing option
To ensure participant safety and with the Sponsor's prior written approval, local laboratory 
testing may  be conducted in lieu of central laboratory  testing, except for PK, immunogenicit y, 
and biomarkers, which must be analyzed by the central laboratory . Thelocal laboratory  must be 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 90qualified in accordance wit h local regulations. Clinically significant laboratory findings must be 
recorded as an AEin the AE eCRF.   However, if possible, laboratory samples collected locally 
or by mobile heal thcare visits should be sent to the cen tral laboratory for analyses .
3.Study intervention and ancillary supplies (including participant diaries)
When aparticipantis unable to goto thesite to receive studysupplies during normal on -site 
visits, the site should work wi th the sponsor to determine appropriate actions .  These act ions may
include: 
asking the participant to go to the site andreceive studysupplies from site staff wit hout 
completion of a full on-site study visit, 
asking theparticipant ’s designee to go to the site andreceive studysupplies on a 
participant’s behalf, and
arranging delivery of study supplies.
Theserequirements m ust be metbefore action is taken :
Alternate delivery  of study intervention should be perform ed in a manner that does not 
compromise treatment blind ing and ensures product integrit y.  The exist ing protocol 
requirements for product accountabilit y remain unchanged, including verification of 
participant’s receipt of study  supplies.
When delivering supplies to a locat ion other than the study  site (for example, 
participant’s ho me), the investigator, sponsor, or bothshould ensure oversight of the 
shipping process to ensureaccountabilit y and product qualit y (that is, storage condi tions 
maintained and intact packaging upon receipt) .
Instructions maybe provided to the participant or designee on the final disposit ion of any 
unused or completed study supplies.
4.Screening period guidance 
The following rules will be applied for active, nonrando mized participants who se participation in 
the study must be paused due to exceptional circumstances :
If paused for l ess than 60days fromVisit 1 to Visit 2: The participant will proceed to 
the next study  visit (Visit 2,liver biopsy) per the usual SoA. 
oThe site should conduct the next visit if the participant’s eligibility criteria are 
confirmed ,and the site should document the reason for delay  in the CRF.
oDue to the pause in screening, sites should also reconfirm the impacted
participant’s consent and document this confirmationin the source 
documentation.
If paused for more than 60 days from Visit 1 to Visi t 2and the patient qualified for a 
liver biopsy fo llowing Visi t 1, then safety  laboratory  parameters and ECGs should be 
collected to assure that a patient may st ill safely undergo a liver biopsy.  If paused for 
more than 120 days from Visit 1 to Visit 2, sites should contact the sponsor medical 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 91monitor to discuss whether the patient should be ascreen-failure, and re-entered as a 
new patient, and then fo llow the SoAto determine eligibilit y for a liver biopsy .
If a patient has an historical liver biopsy ( that is, a biopsy that was performed prior to 
entering Study  GPHR) and there is a pause that results in more than 6 months from 
the date the biopsy was performed to the date of submissio n of the biopsy slides to the 
central laboratory , then the liver biopsy  will need to be repeated, provided the patient 
continues to meet inclusion criteria for a liver biopsy.
5.Adjustments to visit windows
Whenever possible and safe to do so, as determined by the investigator’s discretion , participants 
should complete the usual SoA.  Tomaximize the possibility that these visits can be conducted 
as on-site visits, the windows for visits may be adjusted, upon further guidance fro m thesponsor.  
This minimizes missing data and preserv es the intended conduct of the stud y.
Participants shoul d complete the primarytreatment endpoint vi sit (Visit 14) and the 
final study endpoint follow-up visit (Visit 801) as per the original SoAwhenever 
possible and safe to do so, at the invest igator’s discretion. During periods of 
exceptional circumstance, flexibilit y in Visits 10 (secondary  endpoint), 14 (primary  
treatment endpoint) ,and 801 (final study endpo int follow-up) may occur after 
consultation wit h, and prior approval by the sponsor.
For the secondary  endpoint vi sit (Visit 10, Week 26), the visit windows may  be 
adjusted upon specific guidance from the sponsor.
For participants requiring the visit windowsto be extended, addit ional study drug 
mayneed to be provided to avoid study  drug interrupti on and maintain overall 
integrity of the trial.
Documentation
Changes to study  conduct will be docum ented:
Sites will ident ify and document the details o f how participants, visit ty pes, and 
conducted activit ies were affected by except ional circumstances .
Dispensing/shipment records of study interventionand relevant communicat ions, 
including delegat ion, should be filed with site study records.
Source documents g enerated at a location other than the study site should be part of 
the investigator’s source documentation and should be transferred to the site in a 
secure and t imely manner.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 9210.11. Appendix 11:  Protocol Amendment History
The Protocol Amendment Summary of Chang es Table for the current amendment is located 
directly before the Table of Contents (TOC).
DOCUMENT HISTORY
Document Date
Amendment C 15 Nov ember 2019
Amendment B 21 October 2019
Amendment A 13 August 2019
Original Protocol 26 July 2019
Amendment a
Overall Rationale for the Amendment:
Changes were made to Section 5.1, inclusio n criterion 12 to align wit h regulatory  guidance based 
on the results of preclinical fetal toxicit y studies.
Inclusion criterion 12.b.i has been changed to include the fo llowing:
Men with partners of child -bearing potential, for the duration of the study  and for 5 half-
lives of the study drug plus 90 days after the l ast dose of study  drug (corresponding to 4 
months), will eit her remain abstinent (if this is their preferred and us ual lifestyle) or use 
condoms plus 1 addit ional highly  effective (less than 1% failure rate) method of 
contraception (such as co mbination oral contraceptives, implanted contraceptives or 
intrauterine device) or an effect ive method of contraception (such as male or female 
condoms with spermicide, diaphragms with spermicide or cervical sponges).  Men and 
their partners m ay choose to use a doubl e-barrier method of contraception.
Inclusion criterion 12.b.ii has been changed to clarify  that 5 half -lives of the s tudy drug plus 90 
days after the last dose of study  drug corresponds to 4 months.
Inclusion criterion 12.c.ii has been changed to include the fo llowing:
Otherwise, women of child -bearing potential participat ing must agree to use 2 forms of 
effective contra ception, where at least one form is highly effect ive (less than 1% failure 
rate), for the ent irety of the study  and for 30 day s thereafter.
Furthermore, a statem ent requiring that female participants must not be breast feeding has been 
added (criterion 12.c .iv).
Section # and 
NameDescription of Change Brief Rationale
5.1 Inclusion 
CriteriaUpdated contraceptive informat ionThe contraceptive informat ion for men and 
women has been updated and a statement 
that female part icipants must not be breast 
feeding has been added.
1.3 Schedule Corrected visit window for Visit 14 Clerical error.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 93Section # and 
NameDescription of Change Brief Rationale
of Activitiesin headers subsequent to the first 
page.
Amendment b
Overall Rationale for the Amendment:
Regulatory  feedback from  both the US Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) through the Voluntary  Harmonisation Process (VHP) has resulted in 
changes to the protocol.  These changes incorporate addit ional measures to ensure patient safety 
or clarify procedures.  Other changes are either a re sult of those addi tions or due to inadvertent 
typographical errors.
Section # and Name Description of Change Brief Rationale
1.3. Schedule of 
ActivitiesAdded tem perature to vital signs Regulatory  request
Added laboratory  assessments during the 
dose escalation periodEvaluating laboratory 
parameters at the end of the 
first dose and each dose 
escalation.
Added Thyro id Stimulat ing Hormone 
and Free Fatty  AcidThis was inadvertently o mitted 
from laboratory  assessments
Deleted AST and ALT and glucose lines Line items were deleted 
because they  are part of 
additional safety chemistry  
parameters added by  this 
amendment 
Urine pregnancy  tests have been added 
to all visits beginning at Visit 5.Regulatory  request
Removedtext from footnote jsince FIB4 
will be reported to sites with all 
appropriate measured parametersCorrection based on feedback 
from coordinating laboratory  
4.4. End of Study  
DefinitionAdded wording to clarify  end of study.Regulatory  request
5. StudyPopulation 
(Inclusion and 
Exclusion Criteria)(#2) Added an upper limit on BMI
(#12) Defined combined contraception
(#17) Increased minimum limit for 
platelet count
(#20) Increased minimum limit for 
serum albuminRegulatory  request
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 94Section # and Name Description of Change Brief Rationale
(#20) Reduced maximum direct bilirubin
(#36) Increased minimum eGFR for 
patients on metformin
6.3. Measures to 
Minimize Bias: 
Randomization and 
BlindingExplained purpose of stratificat ion Regulatory  request
6.5 Concomitant 
MedicationAdded caut ionary statement regarding 
rapid gastrointest inally absorbed drugs Tirzepatide initially delays 
gastric emptying, which may 
result in higher exposures of 
concomitant ly administered 
drugs with rapid 
gastrointestinal absorption.
6.5.1.1. 
Hyperglycemia 
Rescue CriteriaLowered the HbA1c criteria for init iating 
hyperglycemia rescue medicat ionRegulatory  request
6.5.1.2. 
Hyperglycemia 
Rescue Medicat ionAdded directions for using met formin 
rescue based on eGFR Regulatory  request
7.1. Discont inuation
of Study 
InterventionAdded pat ient discontinuation criteria 
based on TEAE and SAE severit y and 
relatednessClarifies comm on practice due 
to regulatory  request
7.2.1. 
Discontinuati on of 
Inadvertent ly 
Enrolled PatientsRemoved language stating that patien ts 
who did not meet enrollment criteria 
may stay in the study  in extenuat ing 
circumstances Regulatory  request 
8.1.1. Primary 
Efficacy 
AssessmentAdded informat ion on durati on of 
storage of liver biopsy t issue blocks and 
slidesRegulatory  request
8.2.2.Vital SignsRemoved statem ent regarding sponsor 
supply of equipmentLilly will not be providing 
equipment for m easurement of 
vital signs
8.2.2. Vital Signs Added co llection of temperature to align 
with modified Schedule of Activit ies 
SOA.Regulatory  request
8.2.4.2. Hepatic 
Safety MonitoringReduced the time for fo llow up liver 
testingRegulatory  request
8.3.7.6. 
HypoglycemiaCorrected blood glucose values to align 
with Appendix 4Typographical errors
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 95Section # and Name Description of Change Brief Rationale
9.5. Interim 
AnalysesClarified the interim analyses Regulatory  request
10.1.7.1. 
Discontinuati on of 
StudyOutlined safet y reviews based on Lilly 
Standard Operating Procedures (SOPs) 
Added study  discontinuation criteria 
based on TEAE and SAE severit y and 
relatednessProvides informat ion within 
Lilly SOPs and due to 
regulatory request
10.2. Laboratory  
TestsMoved calcitonin to special laboratory  
testsCalcitonin will be co llected at 
times specified in the SOA 
and not with every  general 
chemistry  collection
Removed text from  footnote hsince 
FIB4 will be reported to sites with all 
appropriate measured parametersCorrection based on feedback 
from coordinating laboratory  
10.3. Liver Safet yAdded text on addit ional liver tests Regulatory  request
Amendment c
Overall Rationale for the Am endment:
Regulatory  feedback from  European Regulatory  Agencies through the Voluntary  Harmonisation 
Process (VHP) has resulted in changes to the protocol.  These changes incorporate addit ional 
measures to ensure patient safety or clarify procedures.  Other changes are either a result of those 
additions or due to inadvertent ty pographical errors.
Section # and 
NameDescription of Change Brief Rationale
4.1. Overall Design Changed 3 to 6 months Regulatory  request
5.1. Inclusio n 
Criteria(#5a) Changed 3 to 6 months Regulatory  request
(#5b) Changed 3 to 6 months Regulatory  request
(#8) Added addit ional language 
clarifying stable body  weightAdditional language added in 
response to regulatory  request 
for liver biopsies up to 6 
months
(#12bi) Language added to clarify  oral 
contraceptivesRegulatory  request
Section # and 
NameDescription of Change Brief Rationale
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 968.1.1. Primary 
Efficacy AssessmentChanged 3 to 6 months Regulatory  request
8.1.1.1. Baseline 
liver biopsyChanged 3 to 6 months in multiple 
placesRegulatory  request
10. Supporting 
Documentation and 
Operational 
ConsiderationsA table including a list of prohibited 
medications by protocol sect ion was 
added as an appendix (Appendix 9) .Regulatory  request
10.3 Appendix 3 
Liver Safety :  
Actions and Fo llow-
Up AssessmentsIn paragraph 3 the word “should” was 
replaced with “may”.Regulatory  request
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 9710.12. Appendix 12:Abbreviations
Term Definition
ADA antidrug antibody
AC Assessment committee 
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an a bnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse events of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
blinding/masking A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and theparticipant are not.
A double-blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of th e subjects 
are aware of the treatment received.
BG blood glucose
BMI body mass index
BP blood pressure
CAP controlled attenuation parameter
CBD cannabidiol
CLDQ-NAFLD Chronic Liver Disease Questionnaire –Nonalcoholic Fatty Liver Disease
CHF congestive heart failure
CI Confidence Interval
CIOMS CouncilforInternational Organizations ofMedicalSciences
Companion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product
Complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a dr ug or drug delivery system.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 98Compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF case report form
CRN Clinical Research Network
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CRS clinical research scientist
CSR clinical study report
CT computed tomography
CV cardiovascular
DILI drug-induced liver injury
DPP-4 dipeptidyl peptidase -4
EAS efficacy analysis set
eCFR electronic case report form
ECG electrocardiogram
EDC electronic data capture
eGFR estimated glomerular filtration r ate
enroll The act of assigning a participant to a treatment.  Participantswho are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB/IRB Ethical Review Board/Institutional Review Board
FAS full analy sis set
FAST FibroScan-AST score
FDA Food and Drug Administration
FIB-4 fibrosis-4
Fibroscan method of transient elastography used for assessment of liver fibrosis
Fibroscan -AST combination of fibroscan with measurement of AST
GCP good clinical practice
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 99GI gastrointestinal
GIP gastric inhibitory polypeptide
GLP-1 glucagon-like peptide -1
HbA1c hemoglobin A1c
HCV hepatitis C virus
HOMA-IR Homeostatic Model Assessments for Insulin Resistance
HRT hormone replacement therapy
IB Investigator’s Brochure
IBD inflammatory bowel disease
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IgE immunoglobulin E
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate.  Informed consent is 
documented by means of a written, signed and dated informed consent form .
INR international normalized ratio
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IQR interquartil e range
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treat ment given.  It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IVRS/IWRS interactive voice -response system/interactive web -response system
LSM liver stiffness measurement
MI myocardial infarction
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 100MMRM mixed model for repeated measures
MRI magnetic resonance imaging
MRI-PDFF MRI –Proton Density Fat Fraction
MTC medullary thyroid carcinoma
NAFLD nonalcoholic fatty liver disease
NAS NAFLD Activity Score
NASH nonalcoholic steatohepatitis
NSAID nonsteroidal anti -inflammatory drug
PGIS Patient Global Impression of Severity
PK/PD pharmacokinetics/pharmacodynamics
PR pulse rate
PROMIS Patient-Reported Outcome Measurement Information System
PRO/ePRO patient-reported outcomes/electronic patient -reported outcomes
QW once weekly
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
Screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SD standard deviation
SGLT-2 sodium-glucose co -transporter -2
SoA
SSSchedule of Activities
safetyanalysis set
SUSARs suspected unexpected serious adverse reactions
T1DM type 2 diabetes mellitus
T2DM type 2 diabetes mellitus
TBL total bilirubin level
TE transient elastography
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 101TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TZD thiazolidinediones
ULN upper limits of n ormal
US United States
WOCBP women of child -bearing potential
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 10211. References
[ADA] American Diabetes Associat ion. Standards of medical care in diabetes –2017. Diabetes 
Care.2017;40(suppl1):S1-S135.
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, 
Mills PR, Keach JC, Lafferty HD,Stahler A, Haflidadotti r S,Bendtsen F . Liver fibrosis, but no 
other histologic features, is associated with long -term outcomes of patients with nonalcoholic 
fatty liver disease. Gastroenterolo gy. 2015;149(2):389-397.
Banks PA, Freeman ML ; Practice Parameters Com mittee of the American Co llege of 
Gastroenterology . Practice guidelines in acute pancreatit is. Am J Gastroenterol . 
2006;101(10):2379 -2400.
Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney  LE, Ajmera V, 
Bettencourt R, Collier S,Hooker J, Sy E,Rizo E,Richards L, Sirlin CB,Loomba R. Optimal 
threshold of controlled attenuation parameter with MRI -PDFF as the gold standard for the 
detection of hepa tic steatosis. Hepatology. 2018;67(4):1348 -1359.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harr ison SA, Brunt EM, 
Sanyal AJ. The diagnosis and management of nonalcoho lic fatty liver disease: Practice 
guidance fro m the American Asso ciation for the Study  of Liver Diseases. Hepatology . 
2018;67(1):328 -357.  
Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA . Frequency and 
outcomes of liver transplantation for nonalcoho lic steatohepatit is in the United States. 
Gastroenterology . 2011;141(4):1249-1253. 
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G , Rossing P, Tsapas 
A, Wexler DJ, Buse JB . Management of Hy perglycemia in Type 2 Diabetes, 2018. A 
Consensus Report by  the American Diabetes Assoc iation (ADA) and the European Associat ion 
for the Study  of Diabetes (EASD) . Diabetes Care . 2018;41(12):2669- 2701. 
[FDA] United States Food and Drug Administration . Noncirrhotic nonalcoholic steatohepatit is 
with liver fibrosis: developing drugs for treatme nt. Draft guidance. Available at: 
https://www.fda.gov/media/119044/download . Published Dec 2018. Accessed 1 May  2019.
[EMA] European Medicines Agency. Reflection paper on regulatory  requirements for the 
development of medicinal products for chronic non -infectious liver diseases (PBC, PSC, 
NASH). Draft. Available at: https://www.ema.europa.eu/en/documents/scient ific-
guideline/reflection -paper-regulatory -requirements-development -medicinal -products-chronic-
non-infectious -liver_en.pdf . Published 15 Nov 2018. Ac cessed 1 May  2019. 
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S , Gimeno RE, Milicevic 
Z,Robins D, Haupt A. Efficacy  and safety of LY3298176, a novel dual GIP and GLP -1 
receptor agonist, in patients with ty pe 2 diabetes: a randomised, pl acebo-controlled and act ive 
comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180- 2193.
Hartman ML, Sanyal A J, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, 
Duffin KL, Robins DA, Haupt A. Effects of novel dual GIP andGLP-1 receptor agonist 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 103tirzepatide on bio markers of nonalcoho lic steatohepatit is in patients with type 2 diabetes .
Diabetes Care.2020;43:1352 -1355.HealthMeasures. Pati ent-Reported Outcome Measurement 
Information System (PROMIS®) website. Available at: 
http://www.h ealthmeasures.net/explore -measurement -systems/promis. Accessed 15 May  2019.
[HHS] Hum an and Health Services. Physical Act ivity Guidelines for Am ericans. Available at 
https://www.hhs.gov/fit ness/be-active/physical -activity-guidelines -for-americans/index.ht ml. 
Published 1 Feb 2019. Accessed 10 May 2019. 
Hsu C, Caussy  C, Imajo K, Chen J, Singh S, Kaulback K, Le MD , Hooker J, Tu X, Bettencourt 
R, Yin M, Sirlin CB, Ehman RL, Nakajima A, Loomba R . Magnetic resonance vs transient 
elastography  analysis of pat ients with nonalcoho lic fatty liver disease: a systemat ic review and 
pooled analysis o f individual participants. Clin Gastroenterol Hepatol . 2019;17(4) :630-637. 
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR. Management of hyperglycemia in t ype 2 diabetes, 2015: a 
patient-centered approach: update to a posit ion statement of the Ameri can Diabetes 
Association and the European Assoc iation for the Study  of Diabetes. Diabetes Care . 
2015;38(1):140 -149.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu 
YC,Torbenson MS, Unalp-Arida A,Yeh M,McCullough AJ, Sanyal AJ; Nonalcoho lic 
Steatohepatit is Clinical Research Network . Design and validat ion of a histo logical scoring 
system for nonalcoholic fatty liver disease. Hepatology . 2005;41(6):1313-1321.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota
M,KimuraY,TakedaK, IsajiS, OtsukiM,Matsuno S. JPN guidelines for the management of 
acute pancreatit is: diagnostic criteria for acute pancreatit is. JHepatobiliary Pancreat Surg . 
2006;13(1):25 -32.
Loomba R, Abraham M, Unalp A, Wilso n L, Lavine J, Doo E, Bass NM; Nonalcohol ic 
Steatohepatit is Clinical Research Network. Association between diabetes, family history of 
diabetes, and ri sk of nonalcoho lic steatohepat itis and fibrosis. Hepatology . 
2012;56(3) :943-951.
Machado M, Marques -Vidal P, Cortez -Pinto H. Hepatic histology  in obese pat ients undergo ing 
bariatric surgery . J Hepatol. 2006;45(4):600 -606. 
Nauck M. Incretin therapies: highlight ing commo n features and differences in the modes of 
action of glucagon -like peptide-1 receptor agoni sts and di peptidyl peptidase -4 inhibitors. 
Diabetes Obes Metab . 2016;18(3):203 -216.
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, 
Zheng MH, Wong VW, Alliso n M, Tsochatzis E, Anstee QM, Sherid an DA, Eddowes PJ, 
Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier -Poizat C, Sandrin L, Harrison 
SA. FibroScan -AST (FAST) score for the non -invasive ident ification of patients with non-
alcoholic steatohepatit is with significant activit y and fibrosis: a prospective derivat ion and 
global validation study . Lancet Gastroenterol Hepatol. 2020;5(4):362 -373. doi: 
10.1016/S2468 -1253(19)30383- 8.
Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of ipragliflozin, a sodium -glucose 
co-transporter 2 inhib itor, as a second -line treatment for non -alcoholic fatty liver disease 
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 104patients with type 2 diabetes m ellitus who do not respon dto incretin-based therapies including 
glucagon-like peptide -1 analogs and dipeptidyl peptidase -4 inhibitors. Clin Drug Investig . 
2016;36(4):313 -319.
Pavlides M, Banerjee R, Tunnicliffe EM, Kelly C, Collier J, Wang LM, Fleming KA , Cobbold 
JF, Robson MD, Neubauer S, Barnes E . Multiparametri c magnetic resonance imaging for the 
assessment of non -alcoholic fatty liver disease severit y.Liver Int. 2017;37(7):1065 -1073.
Promrat K, Kleiner DE, Ni emeier HM, Jackvony  E, Kearns M, Wands JR, Fava JL, Wing RR. 
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatit is. 
Hepatology . 2010;51(1):121 -129. 
Puri P,Sanyal AJ. Nonalcoho lic fatty liver disease: Definit ions, risk factors, and workup. Clin 
Liver Dis. 2012;1(4):99 -103.
Regev A, Palmer M, Avigan MI, Dimick -Santos L, Treem WR, Marcinak JF, Seekins 
D,Krishna G,Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N . Consensus: 
guidelines: best practices for detection, assessment and management of suspected acute 
drug-induced liver injury during clinical trials in patients with nonalcoho lic steatohepatit is. 
Aliment Pharmacol Ther . 2019;49(6):702 -713.
Rockey DC, Caldwell SH, Goodm an ZD, Nel son RC, Smit h AD; American Associat ion for the 
Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49(3):1017 -1044. 
Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, 
McCullough A. Endpo ints and clinical trial design for nonalcoho lic steatohepatit is. 
Hepatology . 2011;54(1):344 -353. 
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA, LEADER Steering 
Committee; LEADER Tri al Investigators. Amylase, lipase, and acute pancreat itis in people 
with type 2 diabetes treated with liraglut ide: Result s from the LEADER randomized trial. 
Diabetes Care . 2017a;40(7):966- 972. [Erratum in:Diabetes Care . 2018 Jul;41(7):1538.]
Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of 
liraglutide on amylase, lipase, and acute pancreat itis in participants with overweight/obesity 
and normoglycemia, prediabetes, or ty pe 2 diabetes: Secondary  analyses of poole d data from  
the SCALE clinical development program. Diabetes Care . 2017b;40(7):830-848.
Trujillo JM, Nuffer W, Ellis SL. GLP -1 receptor agonists: a review of head -to-head clinical 
studies. Ther Adv Endocrinol Metab . 2015;6(1):19 -28.
Van Thiel DH, Ramadori G. Non-viral causes of hepatocellular carcino ma. J Gastrointest 
Cancer.2011;42(4):191 -194. 
Vilar-Gomez E, Martinez -Perez Y, Cal zadilla-Bertot L, Torres -Gonzalez A, Gra -Oramas B, 
Gonzalez -Fabian L, Friedman SL, Diago M, Romero -Gomez M.Weight loss through lifest yle 
modification significant ly reduces features of nonalcoho lic steatohepatit is.Gastroenterology . 
2015;149 (2):367-378.
[WHO] World Healt h Organizat ion. STEPwi se approach to surveillance (STEPS) Section 3, 
Section 3: Data Collect ion Process. Available at: 
http://www.who.int/chp/steps/Part3_Section3.pdf . Published/Updated 26 Jan 2017. Accessed 
10 May 2019.
CONFIDENTIAL Protocol I8F-MC-GPHR(d)
LY3298176 105[WHO] Worl d Health Organizat ion. Healthy d iet. Available at: https://www.who.int/news -
room/fact-sheets/detail/healt hy-diet. Published 23 Oct 2018. Accessed 10 May 2019.
[WHO] World Healt h Organizat ion. Physical  activity and adults. Available at: 
https://www.who.int/dietphysi calactivity/factsheet_adults/en. Accessed 10 May  2019. 
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. 
Prevalence of nonalcoholic fatty liver disease and nonalcoho lic steatohepatit is among a largely 
middle-aged popul ation utilizing ultrasound and liver biopsy: a prospective study . 
Gastroenterology . 2011;140(1):124-131. 
Younossi  ZM, Koenig AB, Abdelat if D, Fazel Y, Henry L, Wymer M. Global epidemio logy of 
nonalcoho lic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and 
outcomes. Hepatology .2016;64(1):73-84
Younossi  ZM, Stepanova M, Henry  L, Racila A, Lam B, Pham HT, Hunt S. A disease -specific 
quality of life instrument for non -alcoholic fatty liver disease and non -alcoholic steatohepatit is: 
CLDQ-NAFLD. Liver Int. 2017;37(8):1209 -1218. 
Younossi  ZM, Stepanova M, Younossi I, Racila A. Validat ion of chronic liver disease 
questionnaire for nonalcoho lic steatohepatit is in patients with biopsy -proven nonalcoholic 
steatohepatit is. Clin Gastroenterol Hepatol. 2019. doi:10.1016/j .cgh.2019.01.001 .
Leo Document ID = 02352495-8534-432d-8ebc-94cfb08672e2
PPD